IMMUNOSTIMULATORY ANTI-CEACAM1 ANTIBODY

Abstract

An anti-CEACAM1 antibody includes at least one antibody heavy chain (V.sub.H) domain having antigen binding sites CDR1.sup.H, CDR2.sup.H and CDR3.sup.H, and at least one antibody light chain (V.sub.L) domain having antigen binding sites CDR1.sup.L, CDR2.sup.L and CDR3.sup.L. The antigen binding site CDR2.sup.H has a sequence homology of at least 80% to the amino acid sequence WINTYTGEPT (SEQ ID No. 21).

Claims

1-15. (canceled)

16: An anti-CEACAM1 antibody comprising: at least one antibody heavy chain (V.sub.H) domain comprising antigen binding sites CDR1.sup.H, CDR2.sup.H and CDR3.sup.H; and at least one antibody light chain (V.sub.L) domain comprising antigen binding sites CDR1.sup.L, CDR2.sup.L and CDR3.sup.L, wherein the antigen binding site CDR2.sup.H has a sequence homology of at least 80% to the amino acid sequence: TABLE-US-00010 WINTYTGEPT. (SEQIDNo.21)

17: The anti-CEACAM1 antibody as recited in claim 16, wherein the anti-CEACAM1 antibody binds an N-domain of CEACAM1 as per SEQ ID No. 39.

18: The anti-CEACAM1 antibody as recited in claim 17, wherein the anti-CEACAM1 antibody further binds at least one further domain selected from the group consisting of an A1-domain of CEACAM1 as per SEQ ID No. 40, a B-domain of CEACAM1 as per SEQ ID No. 41, and a A2-domain of CEACAM1 as per SEQ ID No. 42.

19: The anti-CEACAM1 antibody as recited in claim 16, wherein the antigen binding site CDR2.sup.L has the amino acid sequence: TABLE-US-00011 YTSX.sub.b4LX.sub.b6X.sub.b7, (SEQIDNo.22) wherein, X.sub.b4, X.sub.b6, and X.sub.b7 are each independently of one another an amino acid residue.

20: The anti-CEACAM1 antibody as recited in claim 19, wherein, X.sub.b4 is T or K, X.sub.b6 is Q or H, and X.sub.b7 is P or S.

21: The anti-CEACAM1 antibody as recited in claim 16, wherein the antigen binding site CDR2.sup.L comprises a sequence homology of at least 80% to at least one of the following amino acid sequences: TABLE-US-00012 YTSTLQP, (SEQIDNo.23) and YTSKLHS. (SEQIDNo.24)

22: The anti-CEACAM1 antibody as recited in claim 16, wherein the antigen binding site CDR1.sup.H has the amino acid sequence: TABLE-US-00013 GYX.sub.a3FX.sub.a5X.sub.a6YX.sub.a8MX.sub.a10, (SEQIDNo.25) wherein X.sub.a3, X.sub.a5, X.sub.a6, X.sub.a8 and X.sub.a10 are case independently of one another an amino acid residue.

23: The anti-CEACAM1 antibody as recited in claim 22, wherein, X.sub.a3 is T or I, X.sub.a5 is T or R, X.sub.a6 is selected from the group consisting of V, N and T, X.sub.a8 is G or V, and X.sub.a10 is selected from the group consisting of N, K and H.

24: The anti-CEACAM1 antibody as recited in claim 16, wherein the antigen binding site CDR1.sup.H comprises a sequence homology which is at least 80% to one of the following amino acid sequences: TABLE-US-00014 GYTFTVYGMN, (SEQIDNo.26) GYIFRNYGMK, (SEQIDNo.27) and GYTFTTYVMH. (SEQIDNo.28)

25: The anti-CEACAM1 antibody as recited in claim 16, wherein the antigen binding site CDR1.sup.L has the amino acid sequence: TABLE-US-00015 X.sub.d1ASX.sub.d4X.sub.d5IX.sub.d7X.sub.d8X.sub.d9LX.sub.d11, (SEQIDNo.29) wherein X.sub.d1, X.sub.d4, X.sub.d5, X.sub.d7, X.sub.d8, X.sub.d9 and X.sub.d11 are in each case independently of one another an amino acid residue.

26: The anti-CEACAM1 antibody as recited in claim 25, wherein, X.sub.d1 is a basic amino acid residue, X.sub.d4 is Q or D, X.sub.d5 is D or H, X.sub.d7 is N or S, X.sub.d8 is K or N X.sub.d9 is an aromatic amino acid residue, and X.sub.d11 is A or N.

27: The anti-CEACAM1 antibody as recited in claim 26, wherein, X.sub.d1 is K or R, and X.sub.d9 is selected from the group consisting of F, Y and W.

28: The anti-CEACAM1 antibody as recited in claim 16, wherein the antigen binding site CDR1.sup.L comprises a sequence homology of at least 80% to one of the following amino acid sequences: TABLE-US-00016 KASQDINKFLA, (SEQIDNo.30) RASQDISNYLN, (SEQIDNo.31) and KASDHINNWLA. (SEQIDNo.32)

29: The anti-CEACAM1 antibody as recited in claim 16, further comprising at least one of: a variable antibody heavy chain (V.sub.H) domain comprising a sequence homology of at least 80% to SEQ ID No. 3 or SEQ ID No. 7; and a variable antibody light chain (V.sub.L) domain comprising a sequence homology of at least 80% to SEQ ID No. 5 or SEQ ID No. 9.

30: The anti-CEACAM1 antibody as recited in claim 16, wherein a binding of the anti-CEACAM1 antibody to CEACAM1 comprises a dissociation constant K.sub.d of not greater than 50 nM.

31: An anti-CEACAM1 antibody that binds to an N-domain of CEACAM1 as per SEQ ID No. 39.

32: The anti-CEACAM1 antibody as recited in claim 31, wherein the anti-CEACAM1 antibody further binds to an N-domain of CEACAM1 selected from the group consisting of an A1-domain of CEACAM1 as per SEQ ID No. 40, a B-domain of CEACAM1 as per SEQ ID No. 41, and a A2-domain of CEACAM1 as per SEQ ID No. 42.

33: The anti-CEACAM1 antibody as recited in claim 31, wherein the anti-CEACAM1 antibody comprises: at least one antibody heavy chain (V.sub.H) domain comprising antigen binding sites CDR1.sup.H, CDR2.sup.H and CDR3.sup.H; and at least one antibody light chain (V.sub.L) domain comprising antigen binding sites CDR1.sup.L, CDR2.sup.L and CDR3.sup.L, wherein the antigen binding site CDR2.sup.H has a sequence homology of at least 80% to the amino acid sequence: TABLE-US-00017 WINTYTGEPT. (SEQIDNo.21)

34: A nucleic acid encoding the anti-CEACAM1 antibody as recited in claim 16.

35: A method for at least one of treating and preventing at least one of neoplasias and infections using the anti-CEACAM1 antibody as recited in claim 16, the method comprising, providing the anti-CEACAM1 antibody as recited in claim 1, and administering to a subject in need thereof an effective amount of the anti-CEACAM1 antibody as recited in claim 1.

36: A method for activating T cells in vitro, the method comprising: providing non-activated T cells; contacting the non-activated T cells with: an anti-CEACAM1 antibody as recited in claim 16, and an epitope directed against the T cells, thereby treating the T cells; and culturing the treated T cells under conditions that do not hinder an activation of the T cells.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0023] The present invention is described in greater detail below on the basis of embodiments and of the drawings in which.

[0024] FIG. 1A shows representative continuous-flow cytometry histograms of profilerating B cells of wildtype (WT) or CEACAM1/ mice (CEACAM1-Knockout mice), which were untreated (gray area), treated with anti-CEACAM1 antibody, LPS, or with recombinant mice-CD40 ligand in combination with mouse IL-4 (black line) for 48 hours. DAPI cells are shown (n=6);

[0025] FIG. 1B shows the absolute number of live cells B (DAPI) at stated time points (n=3); sorted from the spleen, after treatment with or without recombinant mouse-CD40 ligand in combination with mouse IL-4 (n=3);

[0026] FIG. 1C shows representative histograms and statistical analysis of Annexin-V+ B cells: which were stimulated with recombinant mouse-CD40 ligand in combination with mouse IL-4 or left unstimulated, after 48 hours (DAPI B cells are shown, n=6);

[0027] FIG. 1D shows the percentage of DAPI+ B cells from the spleen of WT and CEACAM1/ mice after activation with recombinant mouse-CD40 ligand in combination with mouse IL-4 in the presence or absence of Btk inhibitor Ibrutinib cultured for 48 hours determined by FACS analysis (n=6). * P<0.05; ** P<0/01; and *** P<0.001 (Student t-test).

[0028] FIG. 2A shows a scheme of development, maturation and migration of B cells in bone marrow, blood, lymph nodes and spleen;

[0029] FIGS. 2B-E show the total number of B cell subpopulations of wildtype (WT) and CEACAM1/ mice, measured by means of continuous-flow cytometry in bone marrow (b, n=6), in blood (c, n=4), lymph nodes (d, n=4) and in the spleen (e, n=10);

[0030] FIG. 3 shows the total number of B1a and B2 B cell subpopulations (B1a, CD19lowCD5int; B2, CD19highCD5neg) and T cells of wildtype (WT) and CEACAM1/ mice, measured by means of continuous-flow cytometry in the abdominal cavity (n=6). * P<0.05 (Student t-test); ns=not significant.

[0031] FIG. 4 shows the amount of serum immunoglobulins in nave wildtype (WT) and CEACAM1/ mice (n=8 per genotype). ** P<0.01; and *** P<0.001 (Student t-test);

[0032] FIG. 5A shows the percentage of WTVi10 B cells and CEACAM1/Vi10 B cells which were transferred adoptively to WT mice (110.sup.7 per mouse) on day 1 and which were infected with 210.sup.6 PFU of vesicular stromatitis virus (VSV) on day 0. Analysis day 3 after infection (n=3);

[0033] FIGS. 5B-C show the total VSV neutralizing antibodies and neutralizing IgG antibodies in WT and CEACAM1/ mice after intravenous infection with 210.sup.6 PFU VSV (B, n=6-9 per group) and/or after the intravenous infection with 210.sup.8 PFU of UV-inactivated VSV (C, n=8-9 per group);

[0034] FIG. 5D shows the VSV-neutralizing antibody response and neutralizing IgG antibodies in the sera of WT and CEACAM1/ mice that had received 110.sup.7 VSV-specific B cells (Vi10) on day 1 and were then infected with 210.sup.6 PFU VSV on day 0 (n=7-9 per group);

[0035] FIG. 5E shows the VSV titer in various organs of WT and CEACAM1/ mice after intravenous infection with 210.sup.6 PFU VSV analyzed 8 days after infection (n=6 per group);

[0036] FIG. 5F shows the survival of WT and CEACAM1/ mice after intravenous infection with 210.sup.6 PFU VSV (n=9-12 per group);

[0037] FIG. 5G shows the survival of WT and CEACAM1/ mice that were untreated or had been treated adoptively with 110.sup.7 of VSV-specific B cells (Vi10) on day 1 and had been infected on day 0 with 210.sup.6 PFU of VSV (n=4-9). * P<0.05; ** P<0.01; and *** P<0.001 (Student t-test);

[0038] FIG. 6 shows anti-VSV-specific IgM and IgG antibodies in wildtype (WT) and CEACAM1/ mice after intravenous infection with 210.sup.6 PFU of VSV (n=4-7 per group). * P<0.05; ** P<0.01; and *** P<0.001 (Student t-test). Data that are for two experiments (meanSEM);

[0039] FIG. 7A shows the lymphoytic choriomeningitis virus (LCMV) glycoprotein-specific IgG antibody in the serum of wildtype (WT) and CEACAM1/ mice after intravenous infection with 200 PFU of LCMV-WE (n=3-6 per group);

[0040] FIG. 7B shows the liver virus titer of WT and CEACAM1/ mice 10 days after intravenous infection with 210.sup.6 PFU of LCMV-WE (n=3 per group). *** P<0.001 (Student t-test);

[0041] FIG. 8A shows the spleen VSV titer of WT or CEACAM1/ mice 7 h after intravenous infection with 210.sup.6 PFU of VSV (n=6 per genotype). ** P<0.01 (Student t-test);

[0042] FIG. 8B shows the interferon-alpha levels in the serum of WT or CEACAM1/ mice 2 and 4 hours after intravenous infection with 210.sup.8 PFU of VSV;

[0043] FIG. 9 shows the number of auto-antibody-binding cells on liver tissue slices that have been treated with serum of WT and CEACAM1/ mice 100 days after intraperitoneal injection with 500 L of pristane, and fluorescent anti-mouse IgG (n=3-5);

[0044] FIG. 10 shows the amount of virus in different organs of wildtype (WT) or CEACAM1/ mice after infection with 200 PFU of the chronic lymphocytary choriomeningitis virus strain (LCMV docile), measured 10 days after infection (n=3);

[0045] FIG. 11A shows the amount of virus in blood of wildtype (WT) or CEACAM1/ mice which had been treated with control antibodies or anti-CEACAM1 antibodies (200 g day 1) and had additionally been infected on day 0 with 210.sup.4 PFU of the chronic lymphocytary choriomeningitis virus strain (LCMV docile) (n=6);

[0046] FIG. 11B shows alanine-aminotransferase (biomarker for liver damage) in the serum of wildtype (WT) or CEACAM1/ mice which had been treated with control antibodies or anti-CEACAM1 antibodies (200 mg day 1) and had additionally been infected on day 0 with 210.sup.4 PFU of the chronic lymphocytary choriomeningitis virus strain (LCMV docile) (n=6); and

[0047] FIG. 12 shows the amount of virus in different organs of wildtype (WT) mice (measured day 60) that had been infected on day 0 with 210.sup.6 PFU of the chronic lymphocytary choriomeningitis virus strain (LCMV docile) and additionally on day 16 were left untreated or treated with anti-CEACAM1 antibodies (200 g) (n=3-4).

DETAILED DESCRIPTION

[0048] Surprisingly, it has been found that anti-CEACAM1 antibodies that contain an antigen-binding site CDR (Complementarity Determining Region) having at least 80% sequence homology to sequence WINTYTGEPT (SEQ ID No. 21) are particularly highly suitable.

[0049] Accordingly, a first aspect of the present invention relates to an anti-CEACAM1 antibody, comprising [0050] (A) at least one antibody heavy chain (V.sub.H) domain containing antigen binding sites CDR1.sup.H, CDR2.sup.H and CDR3.sup.H, and [0051] (B) at least one antibody light chain (V.sub.L) domain containing antigen binding sites CDR1.sup.L, CDR2.sup.L and CDR3.sup.L, [0052] wherein CDR2.sup.H has at least 80% sequence homology to the following amino acid sequence: [0053] WINTYTGEPT (SEQ ID No. 21).

[0054] According to a preferred embodiment, an antigen binding site CDR2.sup.H of at least 80% sequence homology to the amino acid sequence WINTYTGEPT (SEQ ID No. 21) can also be understood as an amino acid sequence that deviates from SEQ ID No. 21 by no more than two amino acid residues, preferably deviates from SEQ ID No. 21 by no more than a single amino acid residue, in particular is identical in sequence to SEQ ID No. 21.

[0055] Preferably, the dissociation constant K.sub.d of the binding of the anti-CEACAM1 antibody according to the present invention to CEACAM1 is not greater than 100 nM. In other words, the antigen-binding sites CDR1.sup.H, CDR2.sup.H, CDR3.sup.H, CDR1.sup.L, CDR2.sup.L and CDR3.sup.L are selected together such that the anti-CEACAM1 antibody binds to CEACAM1 with a dissociation constant K.sub.d of not greater than 100 nM, preferably not greater than 50 nM.

[0056] As used herein, CEACAM1 is preferably CEACAM1 of a mammal, in particular human CEACAM1.

[0057] The CDRs can be arranged in any sequence. Preferably, in the antibody heavy chain (VH) domain, the CDRs occur in the following sequence from the N to the C terminus: CDR1.sup.H, CDR2.sup.H, CDR3.sup.H. Preferably, in the antibody light chain (VL) domain, the CDRs occur in the following sequence from the N to the C terminus: CDR1.sup.L, CDR2.sup.L, CDR3.sup.L. In each case any number, preferably no more than 50, amino acid residues can be situated between the CDRs situated close to one another.

[0058] Further problems are solved according to the present invention by a substance according to independent embodiment 1 cited hereinafter, a drug according to embodiment 11 cited hereinafter, an antibody according to independent embodiment 12 cited hereinafter, a therapeutic antibody according to independent embodiment 13 cited hereinafter, a variable antibody heavy chain (V.sub.H) domain according to independent embodiment 14 cited hereinafter, a variable antibody light chain (V.sub.L) domain according to independent embodiment 15 cited hereinafter, isolated nucleic acids according to independent embodiments 16 and 17, a B-cell line according to embodiment 18 cited hereinafter, and also a method according to embodiment 19 cited hereinafter. Preferred embodiments are defined in dependent embodiments 2 to 9. The wording of all embodiments is hereby incorporated as contents of the present description by explicit reference.

[0059] In addition, the problems underlying the present invention are solved by the subjects of the present invention disclosed in the description.

[0060] The present invention is based on the following surprising findings:

[0061] Surprisingly, it has been found that the antibodies according to the present invention are suitable for activating T cells. It has been recognized that the antibodies according to the present invention are suitable for the prevention and treatment of neoplasias and infections.

[0062] Surprisingly, it was additionally found that activation of CEACAM1 in mice effects an activation, and in particular differentiation, of B cells and, in addition, permits in particular a beneficial influencing of the course of viral infections, and also infectious diseases. As a virus model, the lymphocytic choriomeningitis virus (LCMV) and vesicular stomatitis virus (VSV) are used. The LCMV is not cytopathic in mice. Therefore, the damage which results from an infection, is primarily caused by the immune response to the virus. Therefore, this virus behaves similar to the weakly cytopathic viruses Hepatitis-B virus (HBV), Hepatitis-C virus (HCV) and human immunodeficiency virus (HIV) in humans. The vesicular stomatitis virus is cytopathic in mice. It therefore behaves similar to the Ebola virus, polio virus, rabies virus, Ebstein-Barr virus (EBV), influenza virus, herpes simplex virus and also cytomegalovirus (CMV).

[0063] In addition, in the context of mice studies, surprisingly, it was shown that inhibition of CEACAM1 in vivo strongly inhibits the activation and differentiation or development of B cells, and in particular hinders the outbreak of a B-cell-dependent autoimmunity. In this case, in mice, a B-cell-dependent autoimmunity was induced by means of pristane. In this case, it was observed that inhibition of CEACAM1 prevented disease in mice. In addition, the inventors found that inhibition of CEACAM1 led to reduced serum-IGE concentrations.

[0064] The term expression, in the context of the present invention, comprises all processes which are required for complete, that is to say functional, expression of the protein CEACAM1. Thus, the term expression, in the context of the present invention, in particular comprises the transcription, subsequent RNA-processing, translation, and also protein maturation, such as, for example, protein folding and post-translational modifications of CEACAM1.

[0065] The phrase function of CEACAM1, in the context of the present invention, defines the physiological function or the physiological functions of CEACAM1, in particular the ability thereof to influence the activity, and in particular differentiation, of B cells.

[0066] As described hereinbefore, the anti-CEACAM1 antibody has an antigen binding site CDR2.sup.H of at least 80% sequence homology to the amino acid sequence WINTYTGEPT (SEQ ID No. 21), the remaining antigen binding sites CDR1.sup.H, CDR3.sup.H, CDR1.sup.L, CDR2.sup.L and CDR3.sup.L) can in principle be variable with respect to the amino acid sequence thereof, but are suitable in their totality for improving the binding of the anti-CEACAM1 antibody to CEACAM1.

[0067] Sequence homology is to be understood in the broadest sense, in particular as sequence homology as according to the BLAST algorithm (Basic Local Alignment Search Tool) of the National Center for Biotechnology Information (NCBI) for protein sequence comparisons (blastp) in the version current on Jul. 14, 2016.

[0068] It is understood that the amino acid sequences, anti-CEACAM1 antibodies, antibody domains, antigen binding sites CDRs etc. shown and described herein can optionally have in each case post-translational modifications such as, for example, glycosylation, sulfation, phosphation, acetylation, acylation, etc. Alternatively, or in addition thereto, the amino acid sequences, anti-CEACAM1 antibodies, antibody domains, antigen binding sites CDRs etc. shown and described herein can in each case have synthetic modifications such as, by way of example, labeling (e.g. fluorophors, binding molecules (biotin, streptavidin, methotrexate etc.). Also, an anti-CEACAM1 antibody can optionally be provided thereby with a radioactive or spin label in such a manner that one of the naturally occurring atoms is replaced by a detectable isotope (e.g. .sup.3H, .sup.13C etc.).

[0069] Preferably, the antibody according to the present invention has an antigen-binding site CDR2.sup.H of at least 90% sequence homology, more preferably of at least 95% sequence homology, in particular with sequence identity, to the amino acid sequence WINTYTGEPT (SEQ ID No. 21).

[0070] According to a preferred embodiment, the anti-CEACAM1 antibody binds the N-domain of CEACAM1 as per SEQ ID No. 39.

[0071] According to a more greatly preferred embodiment, the anti-CEACAM1 antibody binds the N-domain of CEACAM1 as per SEQ ID No. 39, and in addition at least one further domain selected from the group consisting of A1-domain of CEACAM1 as per SEQ ID No. 40, B-domain of CEACAM1 as per SEQ ID No. 41 and A2-domain of CEACAM1 as per SEQ ID No. 42.

[0072] According to a preferred embodiment, the anti-CEACAM1 antibody binds the N-domain of CEACAM1 as per SEQ ID No. 39 and in addition the A1-domain CEACAM1 as per SEQ ID No. 40.

[0073] According to a preferred embodiment, the anti-CEACAM1 antibody binds the N-domain CEACAM1 as per SEQ ID No. 39, and in addition the B-domain of CEACAM1 as per SEQ ID No. 41.

[0074] According to a preferred embodiment, the anti-CEACAM1 antibody binds the N-domain of CEACAM1 as per SEQ ID No. 39 and in addition the A2-domain of CEACAM1 as per SEQ ID No. 42.

[0075] According to a preferred embodiment, the anti-CEACAM1 antibody binds the N-domain CEACAM1 as per SEQ ID No. 39, and in addition the A1-domain of CEACAM1 as per SEQ ID No. 40 and the B-domain of CEACAM1 as per SEQ ID No. 41.

[0076] According to a preferred embodiment, the anti-CEACAM1 antibody binds the N-domain of CEACAM1 as per SEQ ID No. 39, and in addition the A1-domain of CEACAM1 as per SEQ ID No. 40 and the A2-domain of CEACAM1 as per SEQ ID No. 42.

[0077] According to a preferred embodiment, the anti-CEACAM1 antibody binds the N-domain of CEACAM1 as per SEQ ID No. 39 and in addition the B-domain of CEACAM1 as per SEQ ID No. 41 and the A2-domain of CEACAM1 as per SEQ ID No. 42.

[0078] According to a more preferred embodiment, the anti-CEACAM1 antibody binds the N-domain of CEACAM1 as per SEQ ID No. 39 and in addition the A1-domain of CEACAM1 as per SEQ ID No. 40, the B-domain of CEACAM1 as per SEQ ID No. 41, and the A2-domain of CEACAM1 as per SEQ ID No. 42.

[0079] These instances of binding are achieved by the particular antigen-binding site CDR2.sup.H, in particular the particular antigen-binding site CDR2.sup.H in combination with one or more further CDRs in the preferred embodiments.

[0080] Preferably, these instances of binding are in each case a binding in which the dissociation constant K.sub.d of the respective binding is no greater than 1000 nM, more preferably no greater than 500 nM, in particular no greater than 100 nM.

[0081] It is understood that the antibody in each case binds one or more epitopes within these sequences. An epitope can in each case be any type of epitope, such as, e.g. a linear epitope or a structural epitope, a primary epitope or a secondary epitope.

[0082] According to a preferred embodiment, the epitope that is bound by the antibody is 3 to 20 amino acid residues long and consists of 1 to 3 amino acid sequences of the N-domain and also 1 to 3 amino acid sequences of the A1-, B- and/or A2-domain.

[0083] The amino acid sequences SEQ ID Nos 39-42 are as follows:

TABLE-US-00001 SEQIDNo.39:CEACAM1-N-domain (= Ig-likeV-type) QLTTESMPFNVAEGKEVLLLVHNLPQQLFGYSWYKGERVDGNRQIVGYAI GTQQATPGPANSGRETIYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEA TGQFHVYP SEQIDNo.40:CEACAM1-A1-domain (= Ig-likeC2-type1) PKPSISSNNSNPVEDKDAVAFTCEPETQDTTYLWWINNQSLPVSPRLQLS NGNRTLTLLSVTRNDTGPYECEIQNPVSANRSDPVTLN SEQIDNo.41:CEACAM1-B-domain (= Ig-likeC2-type2) PDTPTISPSDTYYRPGANLSLSCYAASNPPAQYSWLINGTFQQSTQELFI PNITVNNSGSYTCHANNSVTGCNRTTVKTII SEQIDNo.42:CEACAM1-A2-domain (= Ig-likeC2-type3) PVVAKPQIKASKTTVTGDKDSVNLTCSTNDTGISIRWFFKNQSLPSSERM KLSQGNTTLS INPVKREDAGTYWCEVFNPISKNQSDPIMLN

[0084] The consensus sequence SEQ ID No. 43 of CEACAM1 is as follows:

TABLE-US-00002 MGHLSAPLHRVRVPWQGLLLTASLLTFWNPPTTAQLTTESMPFNVAEGKE VLLLVHNLPQQLFGYSWYKGERVDGNRQIVGYAIGTQQATPGPANSGRET IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSIS SNNSNPVEDKDAVAFTCEPETQDTTYLWWINNQSLPVSPRLQLSNGNRTL TLLSVTRNDTGPYECEIQNPVSANRSDPVTLNVTYGPDTPTISPSDTYYR PGANLSLSCYAASNPPAQYSWLINGTFQQSTQELFIPNITVNNSGSYTCH ANNSVTGCNRTTVKTIIVTELSPVVAKPQIKASKTTVTGDKDSVNLTCST NDTGISIRWFFKNQSLPSSERMKLSQGNTTLSINPVKREDAGTYWCEVFN PISKNQSDPIMLNVNYNALPQENGLSPGAIAGIVIGVVALVALIAVALAC FLHFGKTGRASDQRDLTEHKPSVSNHTQDHSNDPPNKMNEVTYSTLNFEA QQPTQPTSASPSLTATEIIYSEVKKQ

[0085] A polypeptide of the consensus sequence SEQ ID No. 43 of CEACAM1 preferably forms the following secondary structures (positions): beta-folded sheet (37-46), beta-folded sheet (37-46), beta-folded sheet (51-56), beta-folded sheet (60-73), helix (75-77), beta-folded sheet (78-83), turn (84-87), beta-folded sheet (88-91), beta-folded sheet (99-101), beta-folded sheet (107-109), helix (114-116), beta-folded sheet (118-126), beta-folded sheet (132-141).

[0086] According to a particularly preferred embodiment, the epitope on the CEACAM1-N-domain recognized by the anti-CEACAM1 antibody according to the present invention comprises the amino acid residues Y68, K69, R72, F119 and E133 consensus sequence SEQ ID No. 43 of CEACAM1.

[0087] According to a preferred embodiment, CDR2.sup.L of the antibody according to the present invention has the following amino acid sequence: YTSX.sub.b4LX.sub.b6X.sub.b7 (SEQ ID No. 22), wherein X.sub.b4, X.sub.b6, and X.sub.b7 each independently of one another are any amino acid residue.

[0088] More preferably, in the amino acid sequence YTSX.sub.b4LX.sub.b6X.sub.b7 (SEQ ID No. 22), the residues X.sub.b4, X.sub.b6, and X.sub.b7 are defined in such a manner that: X.sub.b4 is T or K, X.sub.b6 is Q or H, and X.sub.b7 is P or S.

[0089] Accordingly, the residues can be defined as follows: X.sub.b4=T, X.sub.b6=Q and X.sub.b7=P; X.sub.b4=T, X.sub.b6=Q and X.sub.b7=S; X.sub.b4=T, X.sub.b6=H and X.sub.b7=P; X.sub.b4=T, X.sub.b6=H and X.sub.b7=5; X.sub.b4=K, X.sub.b6=Q and X.sub.b7=P; X.sub.b4=K, X.sub.b6=Q and X.sub.b7=5; X.sub.b4=K, X.sub.b6=H and X.sub.b7=P; or X.sub.b4=T, X.sub.b6=H and X.sub.b7=S.

[0090] According to a particularly highly preferred embodiment, CDR2.sup.L has at least 80% sequence homology to one of the following amino acid sequences: YTSTLQP (SEQ ID No. 23), or YTSKLHS (SEQ ID No. 24).

[0091] According to a preferred embodiment, an antigen-binding site CDR2.sup.L of at least 80% sequence homology to the amino acid sequence TSTLQP (SEQ ID No. 23) or YTSKLHS (SEQ ID No. 24) can also be understood as an amino acid sequence that does not deviate from SEQ ID No. 23 or 24 by more than a single amino acid residue, in particular is identical in sequence to SEQ ID No. 23 or 24.

[0092] More highly preferably, CDR2.sup.L has at least 90% sequence homology, still more highly preferably at least 95% sequence homology, in particular sequence identity, to one of the following amino acid sequences: YTSTLQP (SEQ ID No. 23), or YTSKLHS (SEQ ID No. 24).

[0093] Particularly preferably, the antibody according to the present invention has a CDR2.sup.H of an amino acid sequence WINTYTGEPT (SEQ ID No. 21) and a CDR2.sup.L of at least 80% sequence homology to one of the following amino acid sequences: YTSTLQP (SEQ ID No. 23), or YTSKLHS (SEQ ID No. 24).

[0094] According to a preferred embodiment, CDR1.sup.H has the following amino acid sequence:

[0095] GYX.sub.a3FX.sub.a5X.sub.a6YX.sub.a8MX.sub.a10 (SEQ ID No. 25), wherein X.sub.a3, X.sub.a5, X.sub.a6, X.sub.a8 and X.sub.a10 in each case independently of one another are any amino acid residue.

[0096] According to a more highly preferred embodiment, CDR1.sup.H is characterized in that

[0097] X.sub.a3 is T or I,

[0098] X.sub.a5 is T or R,

[0099] X.sub.a6 is selected from the group consisting of V, N and T,

[0100] X.sub.a8 is G or V, and

[0101] X.sub.a10 is selected from the group consisting of N, K and H.

[0102] According to a particularly preferred embodiment, CDR1.sup.H has at least 80% sequence homology to one of the following amino acid sequences: GYTFTVYGMN (SEQ ID No. 26), GYIFRNYGMK (SEQ ID No. 27), or GYTFTTYVMH (SEQ ID No. 28).

[0103] According to a preferred embodiment, an antigen-binding site CDR1.sup.H of at least 80% sequence homology to the amino acid sequence SEQ ID No. 26, 27 or 28 can also be taken to mean an amino acid sequence which deviates by no more than two amino acid residues from SEQ ID No. 26, 27 or 28, more highly preferably deviates by no more than a single amino acid residue from SEQ ID No. 26, 27 or 28, in particular is identical in sequence to SEQ ID No. 26, 27 or 28.

[0104] More highly preferably, CDR1.sup.H has at least 90% sequence homology, still more highly preferably at least 95% sequence homology, in particular sequence identity to one of the following amino acid sequences: GYTFTVYGMN (SEQ ID No. 26), GYIFRNYGMK (SEQ ID No. 27), or GYTFTTYVMH (SEQ ID No. 28).

[0105] According to a preferred embodiment, CDR1.sup.L has the following amino acid sequence: X.sub.d1ASX.sub.d4X.sub.d5IX.sub.d7X.sub.d8X.sub.d9LX.sub.d11 (SEQ ID No. 29), wherein X.sub.d1, X.sub.d4, X.sub.d5, X.sub.d7, X.sub.d8, X.sub.d9 and X.sub.d11, in each case independently of one another, are any amino acid residue.

[0106] According to a more highly preferred embodiment, CDR1.sup.L is characterized in that:

[0107] X.sub.d1 is a basic amino acid residue, in particular K or R,

[0108] X.sub.d4 is Q or D, in particular is Q;

[0109] X.sub.d5 is D or H, in particular is D;

[0110] X.sub.d7 is N or S,

[0111] X.sub.d8 is K or N

[0112] X.sub.d9 is an aromatic amino acid residue, in particular selected from the group consisting of F, Y and W, and in particular is F or Y, and

[0113] X.sub.d11 is A or N.

[0114] According to a still more highly preferred embodiment, CDR1.sup.L is characterized in that:

[0115] X.sub.d1 is a basic amino acid residue, in particular is K or R,

[0116] X.sub.d4 is Q,

[0117] X.sub.d5 is D,

[0118] X.sub.d7 is N or S,

[0119] X.sub.d8 is K or N,

[0120] X.sub.d9 is F or Y, and

[0121] X.sub.d11 is A or N.

[0122] According to a particularly preferred embodiment, CDR1.sup.L has at least 80% sequence homology to one of the following amino acid sequences: KASQDINKFLA (SEQ ID No. 30), RASQDISNYLN (SEQ ID No. 31), or KASDHINNWLA (SEQ ID No. 32).

[0123] According to a preferred embodiment, an antigen-binding site CDR1.sup.L of at least 80% sequence homology to the amino acid sequence SEQ ID No. 30, 31 or 32 can also be taken to mean an amino acid sequence that deviates by no more than two amino acid residues from SEQ ID No. 30, 31 or 32, more highly preferably deviates by no more than a single amino acid residue from SEQ ID No. 30, 31 or 32, in particular is identical in sequence to SEQ ID No. 30, 31 or 32.

[0124] More particularly CDR1.sup.L has at least 90% sequence homology, still more highly preferably at least 95% sequence homology, in particular is identical in sequence to one of the following amino acid sequences: KASQDINKFLA (SEQ ID No. 30), RASQDISNYLN (SEQ ID No. 31), or KASDHINNWLA (SEQ ID No. 32).

[0125] According to a particularly preferred embodiment, CDR2.sup.H, CDR2.sup.L, CDR1.sup.H and CDR1.sup.L are defined as described hereinbefore.

[0126] According to a particularly preferred embodiment, the anti-CEACAM1 antibody has:

[0127] a variable antibody heavy chain (V.sub.H) domain having at least 80% sequence homology to SEQ ID No. 3 or SEQ ID No. 7; and/or

[0128] a variable antibody light chain (V.sub.L) domain having at least 80% sequence homology to SEQ ID No. 5 or SEQ ID No. 9.

[0129] Still more highly preferably, the anti-CEACAM1 antibody according to the present invention has:

[0130] a variable antibody heavy chain (V.sub.H) domain having at least 90% sequence homology to SEQ ID No. 3 or SEQ ID No. 7; and/or

[0131] a variable antibody light chain (V.sub.L) domain having at least 90% sequence homology to SEQ ID No. 5 or SEQ ID No. 9.

[0132] Still more highly preferably, the anti-CEACAM1 antibody according to the present invention has:

[0133] a variable antibody heavy chain (V.sub.H) domain having at least 95% sequence homology to SEQ ID No. 3 or SEQ ID No. 7; and/or

[0134] a variable antibody light chain (V.sub.L) domain having at least 95% sequence homology to SEQ ID No. 5 or SEQ ID No. 9.

[0135] Still more highly preferably, the anti-CEACAM1 antibody according to the present invention has:

[0136] a variable antibody heavy chain (V.sub.H) domain having sequence identity to SEQ ID No. 3 or SEQ ID No. 7; and/or

[0137] a variable antibody light chain (V.sub.L) domain having sequence identity to SEQ ID No. 5 or SEQ ID No. 9.

[0138] According to another particularly preferred embodiment, the anti-CEACAM1 antibody according to the present invention has:

[0139] a variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 3 or SEQ ID No. 7 or an amino acid sequence that deviates from SEQ ID No. 3 or SEQ ID No. 7 by a single amino acid residue; and/or

[0140] a variable antibody light chain (V.sub.L) domain as per SEQ ID No. 5 or SEQ ID No. 9 or an amino acid sequence that deviates from SEQ ID No. 5 or SEQ ID No. 9 by a single amino acid residue.

[0141] Very particularly preferably, the anti-CEACAM1 antibody according to the present invention has:

[0142] a variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 3 or SEQ ID No. 7; and

[0143] a variable antibody light chain (V.sub.L) domain as per SEQ ID No. 5 or SEQ ID No. 9.

[0144] Preferably, the anti-CEACAM1 antibody comprises to the CDR3.sup.H having the following amino acid sequence: X.sub.c1X.sub.c2X.sub.c3X.sub.c4X.sub.c5X.sub.c6X.sub.c7X.sub.c8X.sub.c9X.sub.c10 (SEQ ID No. 33), wherein:

[0145] X.sub.c1 is Y or I,

[0146] X.sub.c2 is R or T,

[0147] X.sub.c3 is Y or T,

[0148] X.sub.c4 is D or S,

[0149] X.sub.c5 is G or N,

[0150] X.sub.c6 is G or Y,

[0151] X.sub.c7 is M or A,

[0152] X.sub.c8 is D or L,

[0153] X.sub.c9 is Y or D, and

[0154] X.sub.c10 is N or is absent.

[0155] Preferably, CDR3.sup.H has at least 80% sequence homology, more highly preferably at least 90% sequence homology, still more highly preferably at least 95% sequence homology, in particular is identical in sequence to one of the following amino acid sequences:

[0156] YRYDGGMDY (SEQ ID No. 34) or ITTSNYALDN (SEQ ID No. 35).

[0157] According to a preferred embodiment, an antigen-binding site CDR3.sup.H of at least 80% sequence homology to an amino acid sequence SEQ ID No. 34 or 35 can also be understood as an amino acid sequence which deviates from SEQ ID No. 34 or 35 by no more than two amino acid residues, or highly preferably deviates from SEQ ID No. 34 or 35 by no more than a single amino acid residue, in particular is identical in sequence to SEQ ID No. 34 or 35.

[0158] Preferably, in addition, the anti-CEACAM1 antibody has a CDR3.sup.L having the following amino acid sequence: X.sub.f1QX.sub.f3X.sub.f4X.sub.f5LX.sub.f7X.sub.f8X.sub.f9 (SEQ ID No. 36), wherein X.sub.f1, X.sub.f3, X.sub.f4, X.sub.f5, X.sub.f7, X.sub.f8 and X.sub.f9 in each case independently of one another are any amino acid residues. Preferably, the amino acid residues are defined in such a manner that:

[0159] X.sub.f1 is L or Q,

[0160] X.sub.f3 is Y or G,

[0161] X.sub.f4 is D or N,

[0162] X.sub.f5 is N or T,

[0163] X.sub.f7 is Y or P,

[0164] X.sub.f8 is T or W,

[0165] X.sub.f9 is T or is absent.

[0166] Preferably, CDR3.sup.L has at least 80% sequence homology, more highly preferably at least 90% sequence homology, still more highly preferably at least 95% sequence homology, in particular is identical in sequence, to one of the following amino acid sequences: LQYDNLYT (SEQ ID No. 37), or QQGNTLPWT (SEQ ID No. 38).

[0167] According to a preferred embodiment, an antigen-binding site CDR3.sup.L of at least 80% sequence homology to the amino acid sequence SEQ ID No. 37 or 38 can also be understood as an amino acid sequence which deviates from SEQ ID No. 37 or 38 by no more than two amino acid residues, more highly preferably deviates from SEQ ID No. 37 or 38 by no more than a single amino acid residue, in particular is identical in sequence to SEQ ID No. 37 or 38.

[0168] According to a preferred embodiment, the anti-CEACAM1 antibody according to the present invention comprises: [0169] a CDR1.sup.H as per SEQ ID No. 25, in particular of at least 80% sequence homology to SEQ ID No. 26, SEQ ID No. 27 or SEQ ID No. 28; [0170] a CDR2.sup.H of at least 80% sequence homology to SEQ ID No. 21; and [0171] a CDR3.sup.H as per SEQ ID No. 33, in particular of at least 80% sequence homology to SEQ ID No. 34 or SEQ ID No. 35.

[0172] According to a preferred embodiment, the anti-CEACAM1 antibody according to the present invention comprises: [0173] a CDR1.sup.H as per SEQ ID No. 25, in particular of at least 80% sequence homology to SEQ ID No. 26, SEQ ID No. 27 or SEQ ID No. 28; [0174] a CDR1.sup.L as per SEQ ID No. 29, in particular of at least 80% sequence homology to SEQ ID No. 30, SEQ ID No. 31 or SEQ ID No. 32; [0175] a CDR2.sup.H of at least 80% sequence homology to SEQ ID No. 21; and [0176] a CDR2.sup.L as per SEQ ID No. 22, in particular of at least 80% sequence homology to SEQ ID No. 23 or SEQ ID No. 24.

[0177] According to a preferred embodiment, the anti-CEACAM1 antibody according to the present invention comprises: [0178] a CDR2.sup.H of at least 80% sequence homology to SEQ ID No. 21; [0179] a CDR2.sup.L as per SEQ ID No. 22, in particular of at least 80% sequence homology to SEQ ID No. 23 or SEQ ID No. 24; [0180] a CDR3.sup.H as per SEQ ID No. 33, in particular of at least 80% sequence homology to SEQ ID No. 34 or SEQ ID No. 35; and [0181] a CDR3.sup.L as per SEQ ID No. 39, in particular of at least 80% sequence homology to SEQ ID No. 37 or SEQ ID No. 38.

[0182] According to a preferred embodiment, the anti-CEACAM1 antibody according to the present invention comprises: [0183] a CDR1.sup.H as per SEQ ID No. 25, in particular of at least 80% sequence homology to SEQ ID No. 26, SEQ ID No. 27 or SEQ ID No. 28; [0184] a CDR1.sup.L as per SEQ ID No. 29, in particular of at least 80% sequence homology to SEQ ID No. 30, SEQ ID No. 31 or SEQ ID No. 32; [0185] a CDR2.sup.H of at least 80% sequence homology to SEQ ID No. 21; [0186] a CDR2.sup.L as per SEQ ID No. 22, in particular of at least 80% sequence homology to SEQ ID No. 23 or SEQ ID No. 24; [0187] a CDR3.sup.H as per SEQ ID No. 33, in particular of at least 80% sequence homology to SEQ ID No. 34 or SEQ ID No. 35; and [0188] a CDR3.sup.L as per SEQ ID No. 39, in particular of at least 80% sequence homology to SEQ ID No. 37 or SEQ ID No. 38,

[0189] wherein the antibody preferably binds the N-domain of CEACAM1 as per SEQ ID No. 39, in particular wherein the antibody preferably binds the N-domain of CEACAM1 as per SEQ ID No. 39 and in addition a further domain selected from the group consisting of A1-domain of CEACAM1 as per SEQ ID No. 40, B-domain of CEACAM1 as per SEQ ID No. 41 and A2-domain of CEACAM1 as per SEQ ID No. 42.

[0190] According to a particularly preferred embodiment, the anti-CEACAM1 antibody according to the present invention comprises: [0191] a CDR1.sup.H of at least 80% sequence homology to SEQ ID No. 26, SEQ ID No. 27 or SEQ ID No. 28; [0192] a CDR1.sup.L of at least 80% sequence homology to SEQ ID No. 30, SEQ ID No. 31 or SEQ ID No. 32; [0193] a CDR2.sup.H of at least 80% sequence homology to SEQ ID No. 21; [0194] a CDR2.sup.L of at least 80% sequence homology to SEQ ID No. 23 or SEQ ID No. 24; [0195] a CDR3.sup.H of at least 80% sequence homology to SEQ ID No. 34 or SEQ ID No. 35; and [0196] a CDR3.sup.L of at least 80% sequence homology to SEQ ID No. 37 or SEQ ID No. 38,

[0197] wherein the antibody preferably binds the N-domain of CEACAM1 as per SEQ ID No. 39, in particular wherein the antibody preferably binds the N-domain of CEACAM1 as per SEQ ID No. 39 and in addition at least one further domain selected from the group consisting of A1-domain of CEACAM1 as per SEQ ID No. 40, B-domain of CEACAM1 as per SEQ ID No. 41 and A2-domain of CEACAM1 as per SEQ ID No. 42.

[0198] According to a very particularly preferred embodiment, the anti-CEACAM1 antibody according to the present invention comprises: [0199] a CDR1.sup.H as per SEQ ID No. 26, SEQ ID No. 27 or SEQ ID No. 28; [0200] a CDR1.sup.L as per SEQ ID No. 30, SEQ ID No. 31 or SEQ ID No. 32; [0201] a CDR2.sup.H as per SEQ ID No. 21; [0202] a CDR2.sup.L as per SEQ ID No. 23 or SEQ ID No. 24; and [0203] a CDR3.sup.H as per SEQ ID No. 34 or SEQ ID No. 35; and [0204] a CDR3.sup.L as per SEQ ID No. 37 or SEQ ID No. 38,

[0205] wherein the antibody preferably binds the N-domain of CEACAM1 as per SEQ ID No. 39, in particular wherein the antibody preferably binds the N-domain of CEACAM1 as per SEQ ID No. 39 and in addition at least one further domain selected from the group consisting of A1-domain of CEACAM1 as per SEQ ID No. 40, B-domain of CEACAM1 as per SEQ ID No. 41 and A2-domain of CEACAM1 as per SEQ ID No. 42.

[0206] The antibody according to the present invention will generally bind to CEACAM1 with a dissociation constant K.sub.d of no more than 1000 nM, preferably binds to CEACAM1 with a dissociation constant K.sub.d of no more than 100 nM.

[0207] According to a preferred embodiment, the binding to CEACAM1 of the antibody according to the present invention has a dissociation constant K.sub.d of no more than 50 nM.

[0208] More highly preferably, the binding of the antibody to CEACAM1 has a dissociation constant K.sub.d of not more than 40 nM, in particular not more than 30 nM.

[0209] Surprisingly, it has been found that the antibody activity is optimum when the antibody binds the N domain and in addition the A1-domain, B-domain or A2-domain.

[0210] Accordingly, the present invention, in a further aspect, also relates to an anti-CEACAM1 antibody that binds to the N-domain of CEACAM1 as per SEQ ID No. 39, and preferably at least one further domain selected from the group consisting of A1-domain of CEACAM1 as per SEQ ID No. 40, B-domain of CEACAM1 as per SEQ ID No. 41 and the A2-domain of CEACAM1 as per SEQ ID No. 42.

[0211] According to a preferred embodiment, the anti-CEACAM1 antibody which is characterized in that it binds to the N-domain of CEACAM1 and at least one further of said domains, also has other properties as described hereinbefore.

[0212] It will be understandable to a person skilled in the art that the antibodies are generally obtained via gene expression. Therefore, a further aspect of the present invention relates to a nucleic acid encoding one of the anti-CEACAM1 antibodies according to the present invention.

[0213] Likewise, the present invention relates to cells, in particular mammalian cells, that contain such a nucleic acid.

[0214] The present invention also relates to the therapeutic, preventive, and in vitro application of the antibody. Therefore, an aspect relates to the anti-CEACAM1 antibody according to the present invention for use as a drug.

[0215] As noted hereinbefore, the anti-CEACAM1 antibody according to the present invention is suitable for prevention of neoplasias and infections.

[0216] Therefore, a further of the present invention relates to the anti-CEACAM1 antibody according to the present invention for use in a method for treatment and/or prevention of neoplasias and/or infections.

[0217] In other words, the present invention relates to a method for treatment and/or prevention of neoplasias and/or infections, comprising the administration of a sufficient amount to the patients that are to be treated.

[0218] According to a preferred embodiment, neoplasias are malign tumors and/or cancer and/or infections viral infections, or viral infectious diseases. These are described herein in more detail.

[0219] It will be understood that the anti-CEACAM1 antibody according to the present invention, for such a therapeutic or preventive use, can be dissolved in a suitable pharmaceutically compatible liquid or pasty carrier. Therefore, an aspect of the present present invention also relates to a pharmaceutical composition containing at least one anti-CEACAM1 antibody according to the present invention and at least one pharmaceutically compatible carrier. By way of example, a pharmaceutically compatible carrier can be an aqueous buffer (e.g. a hepes, tris or phosphate buffer), an organic solvent (e.g. dimethyl sulfoxide (DMSO), ethanol) or a mixture or two or more thereof.

[0220] As described above, the anti-CEACAM1 antibodies according to the present invention surprisingly are also suitable for activating T cells. This can also proceed ex vivo and therefore in vitro.

[0221] A further aspect of the present invention therefore relates to a method for activating T cells in vitro, comprising the following steps: [0222] (i) providing non-activated T cells; [0223] (ii) contacting the non-activated T cells with: [0224] (a) an anti-CEACAM1 antibody as claimed in any one of claims 1 to 12, and [0225] (b) an epitope against which the T cells are directed; and [0226] (iii) culturing the T cells that are treated as per step (ii) under conditions that do not hinder the activation of the T cells.

[0227] T cells are preferably CD8-positive T cells. The T cells can be taken from a patient or can originate from a cell culture. The culturing conditions are preferably about 37 C. in nutrient solution at approximately pH 7.1-7.4 for some hours or days. The method is also elucidated by way of example in the examples hereinafter.

[0228] The term antibody, as used herein, should be taken to mean in the broadest sense as any type of immunoglobulin or antigen-binding fragment of one such. Numerous forms of antibodies are known in the prior art. In addition to the antibody heavy chain (V.sub.H) domain and the antibody light chain (V.sub.L) domain, the antibody can be made in any way. In the experiments, a mouse-antibody was used. A person skilled in the art knows directly how such a mouse antibody is made up and is available. The constant part of the antibody (Fc) is then mouse-typical. The antibody can be humanized, in particular for therapeutic and/or preventive application.

[0229] By way of example, the antibody can be: Immunoglobulin A (IgA), Immunoglobulin D (IgD), Immunoglobulin E (IgE), Immunoglobulin G (IgG), Immunoglobulin M (IgM), Immunoglobulin Y (IgY) and Immunoglobulin W (IgW). Preferred antibodies are selected from the group consisting of IgA, IgG and IgD, in particular IgG. According to a preferred embodiment, the antibody according to the present invention is a humanized antibody, in particular a humanized IgG antibody.

[0230] An antigen binding fragment, in the context of the present invention, also has an antigen-binding site CDR2.sup.H of at least 80% sequence homology to an amino acid sequence WINTYTGEPT (SEQ ID No. 21), the remaining antigen-binding sites CDR1.sup.H, CDR3.sup.H, CDR1.sup.L, CDR2.sup.L and CDR3.sup.L are variable. An example of an antigen-binding fragment is a fragment antigen binding (Fab fragment), a truncated antibody having one or two CDR regions, or an isolated variable fragment (Fv) of an antibody.

[0231] The antibodies disclosed in the context of the present invention preferably have in each case a structure characteristic of antibodies: They each have two identical heavy polypeptide chains and two identical light polypeptide chains, which are linked to one another by covalent disulfide bonds to form a Y-shape structure. The light chains each consist of a variable domain, hereinafter termed variable antibody light chain (V.sub.L) domain, and a constant domain, hereinafter called constant antibody light chain (CO domain. The heavy chains, in contrast, each have a variable domain, hereinafter called variable antibody heavy chain (V.sub.H) domain, and three constant domains, hereinafter called constant antibody heavy chain (C.sub.H) domains. If, accordingly, in the context of the present invention, a variable antibody heavy chain (V.sub.H) domain of the antibody is mentioned, or a variable antibody light chain (V.sub.L) domain of the antibody is mentioned, this means that the antibody in total has two variable antibody heavy chain (V.sub.H) domains, namely one variable antibody heavy chain (V.sub.H) domain per heavy chain, or two variable antibody light chain (V.sub.L) domains, namely one variable antibody light chain (V.sub.L) domain per light chain, having the features disclosed hereinafter. The same applies correspondingly if, hereinafter, a constant antibody light chain (CO domain of the antibody is mentioned. If hereinafter constant antibody heavy chain (C.sub.H) domains of the antibody are mentioned, this means the constant antibody heavy chain (C.sub.H) domains of both heavy chains of the antibody.

[0232] According to a further aspect, the present invention relates to the use of an anti-CEACAM1 antibody as immunostimulant, wherein this is optionally used in combination with one or more other immunostimulants (e.g. TLR agonists, T-cell ligands etc.).

[0233] In other words, the present invention relates to an anti-CEACAM1 antibody for activating immune cells, in particular T cells.

[0234] Preferably, in this case, the anti-CEACAM1 antibody is an anti-CEACAM1 antibody according to the present invention as described herein.

[0235] An anti-CEACAM1 antibody, in particular an anti-CEACAM1 antibody according to the present invention as described herein can bring one or more CEACAM1 polypeptides and optionally other polypeptides into a shared configuration. This can lead to the activation of a CEACAM1-mediated signal transduction pathway, which in turn can activate T cells. An anti-CEACAM1 antibody, in particular an anti-CEACAM1 antibody according to the present invention, as described herein, can reinforce the action of immunostimulatory ligands.

[0236] According to a further aspect, the present invention proposes a substance (in particular an anti-CEACAM1 antibody according to the present invention) for use in the therapy, i.e. treatment and/or prevention, of viral infections and/or viral infectious diseases, preferably in humans or nonhuman animals. The substance can be provided, in particular for use in inoculation against viral infectious diseases, or be used for inoculation against viral infectious diseases.

[0237] According to a further aspect, the present invention relates to a substance (in particular an anti-CEACAM1 antibody according to the present invention) for use in the therapy, i.e. treatment and/or prevention, of bacterial infections and/or bacterial infectious diseases, preferably in humans or nonhuman animals. The substance can be provided, in particular for use in inoculation against bacterial infectious diseases, or be used for inoculation against bacterial infectious diseases.

[0238] According to a further aspect, the present invention relates to a substance (in particular an anti-CEACAM1 antibody according to the present invention) for use in the therapy, i.e. treatment and/or prevention, of sepsis.

[0239] The substance is distinguished particularly in that it activates CEACAM1, preferably the expression and/or function of CEACAM1.

[0240] In particular, the substance is an anti-CEACAM1 antibody according to the present invention.

[0241] Preferably, the CEACAM1 is EACAM1 as per SEQ ID No. 1 (therefore the expression product of SEQ ID No. 1) or CEACAM1 as per SEQ ID No. 43.

[0242] In an alternative embodiment, the CEACAM1 is CEACAM1 as per SEQ ID No. 2 (therefore the expression product of SEQ ID No. 2). The CEACAM1 as per SEQ ID No. 2, in contrast to the CEACAM1 as per SEQ ID No. 1, possesses what is termed an interleukin-2 secretory sequence (IL-2 secretory sequence). This sequence leads to the protein pursuing the secretory pathway, and therefore being secreted by cells. Without this modification, the protein would not be secreted.

[0243] The expression and/or function of CEACAM1 can be activated by the substance provided according to the present invention in differing ways.

[0244] According to the present invention, it can be envisaged, for example, that the substance activates the expression of CEACAM1 at the nucleic acid level.

[0245] In addition, it can be envisaged that the substance activates the expression of CEACAM1 by activating an endogenous CEACAM1 promoter.

[0246] In addition, it can be provided that the substance activates the expression of CEACAM1 at the mRNA level.

[0247] In addition, it can be provided according to the present invention that the substance activates CEACAM1 at the protein level.

[0248] In a further embodiment, the substance is a polynucleotide which encodes a polypeptide or protein, wherein the polypeptide or protein activates the expression and/or function of CEACAM1.

[0249] The substance provided according to the present invention preferably binds, in particular forming a crosslinking, to CEACAM1. The crosslinking leads to the fact that CEACAM1 molecules congregate in the membrane and, by interaction with themselves or other signal proteins, develop their action in the cell.

[0250] In a preferred embodiment, the substance is a substance directed toward CEACAM1.

[0251] The substance can in addition be in particular directed toward inhibitors, biological precursors and/or variants, in particular isoforms, of CEACAM1.

[0252] In principle, the substance can be selected from the group consisting of anti-sense RNA, aptamers, mirror aptamers, antibodies, soluble binding partners, in particular soluble ligands, of CEACAM1, soluble receptors, small interfering RNA (siRNA), small hairpin RNA (shRNA), siRNA-containing particles (such as siRNA-containing calcium phosphate particles), shRNA-containing particles (such as shRNA-containing calcium phosphate particles), siRNA-containing vesicles (such as siRNA-containing liposomes), shRNA-containing vesicles (such as siRNA-containing liposomes) and ribozymes. Preferably, the siRNA and shRNA are present in the siRNA-containing particles and shRNA-containing particles in packaged form.

[0253] According to a particularly preferred embodiment, the substance is an antibody directed toward CEACAM1 (anti-CEACAM1 antibody, activating antibody).

[0254] The antibody, in a further embodiment, is a murine antibody or leporine antibody. In other words, it can be preferred according to the present invention if the antibody is a rabbit antibody, mouse antibody or rat antibody, i.e. is an antibody which has been produced by a rabbit, a mouse or a rat.

[0255] The antibody can have, in particular, a variable antibody heavy chain (V.sub.H) domain which is selected from the group consisting of variable antibody heavy chain (V.sub.H) domains of murine origin and variable antibody heavy chain (V.sub.H) domains of leporine origin. In other words, it can be provided in particular according to the present invention that the antibody has a variable antibody heavy chain (V.sub.H) domain which has been produced by a mouse, a rat or a rabbit.

[0256] In addition, the antibody can have in particular a variable antibody light chain (V.sub.L) domain which is selected from the group consisting of variable antibody light chain (V.sub.L) domain of murine origin and variable antibody light chain (V.sub.L) domain of leporine origin. In other words, it can be provided according to the present invention, in particular, that the antibody has a variable antibody light chain (V.sub.L) domain which has been produced from a mouse, a rat or a rabbit.

[0257] To improve the compatibility of the antibody, in a further embodiment, it can be provided that the antibody has constant antibody heavy chain (C.sub.H) domains of human origin and/or a constant antibody light chain (CO domain of human origin.

[0258] According to a preferred embodiment, the antibody is a humanized antibody. In this embodiment, the constant antibody heavy chain (C.sub.H) domain and also the constant antibody light chain (CO domain of the antibody are in each case of human origin, whereas the variable antibody heavy chain (V.sub.H) domain and variable antibody light chain (V.sub.L) domain of the antibody are in each case of xenogenic, in particular murine or leporine, origin.

[0259] The antibody preferably has a variable antibody heavy chain (V.sub.H) domain which is selected from the group consisting of variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 3, variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 7 and variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 11.

[0260] In a further preferred embodiment, the antibody has a variable antibody light chain (V.sub.L) domain which is selected from the group consisting of variable antibody light chain (V.sub.L) domain as per SEQ ID No. 5, variable antibody light chain (V.sub.L) domain as per SEQ ID No. 9 and variable antibody light chain (V.sub.L) domain as per SEQ ID No. 13.

[0261] Particularly preferably, the antibody has a variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 3 and a variable antibody light chain (V.sub.L) domain as per SEQ ID No. 5.

[0262] In an alternative embodiment, the antibody has a variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 7 and a variable antibody light chain (V.sub.L) domain as per SEQ ID No. 9.

[0263] According to a further alternative embodiment, the antibody has a variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 11 and a variable antibody light chain (VL) domain as per SEQ ID No. 13.

[0264] In a preferred embodiment, the antibody has a variable antibody heavy chain (V.sub.H) domain which is encoded by a nucleotide sequence which is selected from the group consisting of SEQ ID No. 4, SEQ ID No. 8 and SEQ ID No. 12.

[0265] According to a further preferred embodiment, the antibody has a variable antibody light chain (V.sub.L) domain which is encoded by a nucleotide sequence which is selected from the group consisting of SEQ ID No. 6, SEQ ID No. 10 and SEQ ID No. 14.

[0266] In a particularly preferred embodiment, the antibody has a variable antibody heavy chain (V.sub.H) domain which is encoded by a nucleotide sequence as per SEQ ID No. 4, and a variable antibody light chain (VL) domain which is encoded by a nucleotide sequence as per SEQ ID No. 6.

[0267] According to an alternative embodiment, the antibody has a variable antibody heavy chain (V.sub.H) domain which is encoded by a nucleotide sequence as per SEQ ID No. 8, and a variable antibody light chain (VL) domain which is encoded by a nucleotide sequence as per SEQ ID No. 10.

[0268] According to a further alternative embodiment, the antibody has a variable antibody heavy chain (V.sub.H) domain which is encoded by a nucleotide sequence as per SEQ ID No. 12, and a variable antibody light chain (VL) domain which is encoded by a nucleotide sequence as per SEQ ID No. 14.

[0269] In addition, the antibody is preferably a monoclonal antibody.

[0270] The antibody, in a further embodiment, can be an antibody that is produced by a B-cell hybridoma line (B-cell clone) which is selected from the group consisting of 6G5J, B3-17 and 18-20.

[0271] According to further embodiments, the substance provided according to the present invention can be a natural binding partner of CEACAM1 or a modified form of such a binding partner. For example, the substance can be selected from the group consisting of soluble UspAl protein of Moraxella catarrhalis, modified UspAl protein of Moraxella catarrhalis, soluble Opa protein of Neisseria gonorrhoeae, modified Opa protein of Neisseria gonorrhoeae, soluble variable P5 protein of Haemophilus influenzae, modified variable P5 protein of Haemophilus influenzae, modified Tim3, modified glycoprotein of hepatitis virus, modified salmonella surface protein and modified Escherichia coli surface protein.

[0272] In a preferred embodiment, the substance is the soluble protein UspAl of Moraxella catarrhalis as per SEQ ID No. 15.

[0273] In a further embodiment, the substance is the soluble protein UspAl of Moraxella catarrhalis, which is encoded by a nucleotide sequence as per SEQ ID No. 16.

[0274] In a further embodiment, the substance is the soluble protein Opa of Neisseria gonorrhoeae as per SEQ ID No. 17.

[0275] In a further embodiment, the substance is a soluble variable protein P5 of Haemophilus influenzae as per SEQ ID No. 18.

[0276] In a further embodiment, the substance is the soluble human recombinant CEACAM1 fusion protein as per SEQ ID No. 19.

[0277] In a further embodiment, the substance is the soluble human recombinant CEACAM1-fusion protein which is encoded by a nucleotide sequence as per SEQ ID No. 20.

[0278] The viral infections or infectious diseases are preferably selected from the group consisting of viral hepatitis, hepatitis B, hepatitis C, HIV infection, Aids, influenza, Poliomyelitis, virus-induced myocarditis, Epstein-Barr virus infections or infectious diseases such as glandular fever, herpes simplex, cytomegalie, rabies and Ebola.

[0279] According to a further aspect, the present invention relates to a substance for use in the therapy, i.e. treatment and/or prevention, of B-cell-dependent diseases, preferably in humans or nonhuman animals.

[0280] The substance is distinguished particularly in that it inhibits CEACAM1, preferably the expression and/or function of CEACAM1.

[0281] The expression and/or function of CEACAM1 can be inhibited by the substance provided according to the present invention in different ways.

[0282] According to the present invention, it can be provided that the substance inhibits the expression of CEACAM1 at the nucleic acid level.

[0283] In addition, it can be provided that the substance inhibits the expression of CEACAM1 by activating an endogenous CEACAM1 promoter.

[0284] In addition, it can be provided that the substance inhibits the expression of CEACAM1 at the mRNA level.

[0285] In addition, it can be provided according to the present invention that the substance inhibits CEACAM1 at the protein level.

[0286] In a further embodiment, the substance is a polynucleotide which is encoded by a polypeptide or protein, wherein the polypeptide or protein inhibits the expression and/or function of CEACAM1.

[0287] The B-cell-dependent diseases are, preferably, autoimmune diseases and/or inflammatory diseases.

[0288] Preferably, the autoimmune diseases or inflammatory diseases are selected from the group consisting of Myasthenia gravis, systemic Lupus erythematodes, autoimmune thyroiditis, dermatitis such as atopic dermatitis and/or eczema, psoriasis, Sjgren's syndrome, Crohn's disease, conjunctivitis, Cholitis ulcerosa, bronchial asthma, allergic asthma, Lupus erythematodes such as cutaneous Lupus erythematodes, allergies, Wegener's disease (granulomatosis polyangiitis), Stevens-Johnson syndrome, sprue, Basedow's disease, sarcoidosis, primary biliary cirrhosis, autoimmune hepatitis, diabetes mellitus such as diabetes mellitus type 1 and/or diabetes mellitus type 2, arthritis such as rheumatoid arthritis, osteoarthritis and/or psoriasis arthritis, multiple sclerosis and B-cell lymphoma.

[0289] With respect to further features and advantages of the substance, to avoid unnecessary repetitions, reference is made in its entirety to the details made in the context of the first aspect of the present invention. The embodiments and advantages described there apply accordingly also to the substance according to the second aspect of the present invention.

[0290] According to a further aspect, the present invention relates to a drug, preferably for use in the therapy, i.e. treatment and/or prevention, of viral infections, viral infectious diseases and/or B-cell-dependent diseases, in particular in human or nonhuman animals.

[0291] The drug is distinguished particularly in that it contains at least one substance as per an aspect of the present invention cited above.

[0292] Preferably, the drug additionally contains a pharmaceutically compatible carrier material. As suitable carrier materials, in principle inorganic and/or organic carrier materials come into consideration. For example, the carrier can be selected from the group consisting of water, vegetable oils, fatty compounds, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as lactose and/or starch, magnesium stearate, tallow, Vaseline and mixtures thereof. With respect to suitable carrier materials, reference may be made for example to the textbook by Bauer et al. (Lehrbuch der Pharmazeutischen Technologie [Textbook of Pharmaceutical Technology], 6th edition, 1999, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, Germany) and also to the textbook by Rowe et al. (Handbook of Pharmaceutical Excipients, 5th edition, 2006, Pharmaceutical Press and American Pharmacists Association), the disclosure of which with respect to the carrier materials described there is incorporated into the contents of the present description by explicit reference.

[0293] According to the present invention, it can additionally be provided that the drug in addition contains at least one auxiliary which is selected, for example, from the group consisting of lubricants, preservatives, stabilizers, resorption accelerators, wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, dyes, flavorings, perfumes, further active ingredients and mixtures thereof.

[0294] The drug can be, in particular, an inoculate against viral infectious diseases.

[0295] With respect to further features and advantages of the drug, in particular of the at least one substance, the viral infections, viral infectious diseases and/or B-cell-dependent diseases, to avoid unnecessary repetitions, reference is made in its entirety to the description to date. The embodiments and advantages described there with respect to the substance and also the viral infections, viral infectious diseases and/or B-cell-dependent disease mentioned there apply accordingly also to the drug according to the third aspect of the present invention.

[0296] According to a further aspect, the present invention relates to a substance for use in the diagnosis of viral infections, viral infectious disease and/or B-cell-dependent diseases, preferably in humans or nonhuman animals.

[0297] The substance is distinguished particularly in that it is provided or used for detecting CEACAM1, preferably for detecting the expression and/or function of CEACAM1.

[0298] Detecting the expression and/or function of CEACAM1 by the substance provided according to the present invention can proceed in various ways.

[0299] According to the present invention, it can be provided, for example, that the substance is used for detecting the expression of CEACAM1 at the nucleic acid level.

[0300] In addition, it can be provided that the substance is used for detecting the expression of CEACAM1 at the mRNA level.

[0301] In a further embodiment, the substance is a polynucleotide which encodes a polypeptide or protein, wherein the polypeptide or protein inhibits the expression and/or function of CEACAM1.

[0302] In a preferred embodiment, the substance is a substance directed against CEACAM1.

[0303] Particularly preferably, the substance directed against CEACAM1 is an antibody (anti-CEACAM1 antibody). Such an antibody can be used in the context of detection methods known to those skilled in the art, for example ELISA (Enzyme-Linked Immunosorbent Assay). In the case of ELISA, a specific antibody directed toward the antigen (CEACAM1) that is to be determined is bound to a carrier material, for example cellulose or polystyrene. On the carrier material, after an incubation with a sample that contains CEACAM1 as antigen, immune complexes form. In a subsequent step, to these immune complexes are added a labeled antibody which is likewise directed against the antigen CEACAM1, but expediently binds at a different site than the antibody bound to the carrier material. This labeled antibody is usually an antibody-enzyme conjugate, wherein the enzyme is generally alkali phosphatase or horseradish peroxide. By adding the labeled antibody, ultimately ternary complexes form from the antigen (CEACAM1) and the two antibodies directed in each case against the antigen (CEACAM1). These ternary complexes may be visualized by adding chromogenic substrates, such as, for example, para-nitrophenol. The concentration of CEACAM1 in the sample can be determined therefrom via photometric determination of the immune complex bound marker enzymes by comparison with standards of known antigen concentration. It is likewise possible to use antibodies directed against CEACAM1 (anti-CEACAM1 antibodies) in the context of ELISPOT methods. The methods mentioned in this paragraph are sufficiently familiar to those skilled in the art so that further explanations are dispensed with.

[0304] In a further embodiment, the substance can be an oligonucleotide which is suitable, for example by means of what is termed the polymerase chain reaction (PCR), to amplify selectively certain DNA sections of CEACAM1, and in this manner to produce a preferably quantitative detection of CEACAM1.

[0305] According to a further embodiment, the substance can be an oligonucleotide or polynucleotide which is hybridized with CEACAM1 under stringent conditions. With the aid of such oligonucleotides or polynucleotides, for example Southern Blots or Northern Blots can be carried out, in order in this manner to detect the DNA or RNA content of CEACAM1. In this manner, for example the transcription rate of CEACAM1 may also be investigated. Corresponding methods are likewise sufficiently familiar to those skilled in the art such that further details are likewise dispensed with at this point.

[0306] With respect to further features and advantages of the substance and also with respect to possible viral infections, viral infectious diseases and/or B-cell-dependent diseases, to avoid unnecessary repetitions, likewise reference is made completely to the description above. The embodiments and advantages described there with respect to the substance and also the viral infections, viral infectious diseases and/or B-cell-dependent diseases mentioned there apply accordingly also to the substance according to the fourth aspect of the present invention.

[0307] According to a further aspect, the present invention relates to a diagnostic agent, preferably for use in the diagnosis of viral infections, viral infectious diseases and/or B-cell-dependent diseases, in particular in humans or nonhuman animals.

[0308] The diagnostic agent is distinguished particularly in that it contains at least one substance according to an abovementioned aspect of the present invention.

[0309] With respect to further features and advantages of the diagnostic agent, in particular of the at least one substance, the viral infections, viral infectious diseases and/or B-cell-dependent diseases, likewise reference is made in its entirety to the description to date. The embodiments and advantages described there with respect to the substance and also the viral infections, viral infectious diseases and/or B-cell-dependent diseases mentioned there also apply similarly to the diagnostic agent as per the fifth aspect of the present invention.

[0310] According to a further aspect, the present invention relates to an antibody directed against CEACAM1 (anti-CEACAM1 antibody).

[0311] The antibody is distinguished particularly in that it comprises a variable antibody heavy chain (V.sub.H) domain selected from the group consisting of variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 3, variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 7 and variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 11, and/or a variable antibody light chain (V.sub.L) domain, selected from the group consisting of variable antibody light chain (V.sub.L) domain as per SEQ ID No. 5, variable antibody light chain (V.sub.L) domain as per SEQ ID No. 9 and variable antibody light chain (V.sub.L) domain as per SEQ ID No. 13.

[0312] The antibody, in a preferred embodiment, has a variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 3 and a variable antibody light chain (V.sub.L) domain as per SEQ ID No. 5.

[0313] In an alternative embodiment, the antibody has a variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 7 and a variable antibody light chain (V.sub.L) domain as per SEQ ID No. 9.

[0314] In a further alternative embodiment, the antibody has a variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 11 and a variable antibody light chain (V.sub.L) domain as per SEQ ID No. 13.

[0315] The antibody, in a preferred embodiment, is a murine antibody or leporine antibody. In other words, it is preferred according to the present invention when the antibody is a mouse antibody, rat antibody or rabbit antibody, i.e. an antibody which has been produced by a mouse, a rat, or a rabbit.

[0316] In particular, the variable antibody heavy chain (V.sub.H) domain can be selected from the group consisting of variable antibody heavy chain (V.sub.H) domain of murine origin and variable antibody heavy chain (V.sub.H) domain of leporine origin. In other words, according to the present invention it can be provided in particular that the variable antibody heavy chain (V.sub.H) domain has been produced by a mouse, a rat or a rabbit.

[0317] In addition, in particular the variable antibody light chain (V.sub.L) domain can be selected from the group consisting of variable antibody light chain (V.sub.L) domain of murine origin and variable antibody light chain (V.sub.L) domain of leporine origin. In other words, according to the present invention it can be provided in particular that the variable antibody light chain (V.sub.L) domain has been produced by a mouse, a rat or a rabbit.

[0318] To improve the compatibility of the antibody, in a further embodiment, it can be provided that the antibody has a constant antibody heavy chain (C.sub.H) domain of human origin and/or a constant antibody light chain (CO domain of human origin.

[0319] According to a further embodiment, the antibody is a humanized antibody. In this embodiment, the constant antibody heavy chain (C.sub.H) domain and also the constant antibody light chain (CO domain of the antibody are each of human origin, whereas the variable antibody heavy chain (V.sub.H) domain and variable antibody light chain (V.sub.L) domain of the antibody are each of xenogenic origin, in particular murine or leporine origin.

[0320] In addition, the antibody is preferably a monoclonal antibody.

[0321] The antibody can be, in particular, an antibody which is produced by a B cell hybridoma line (B cell clone), which is selected from the group consisting of 6G5J, B3-17 and 18-20.

[0322] The antibody is in addition preferably an antibody for use in medicine.

[0323] In principle, the antibody can be a diagnostic and/or therapeutic antibody. Correspondingly, the antibody can be provided for use in the diagnosis and/or therapy, i.e. treatment and/or prevention, of diseases.

[0324] In principle, the antibody can be an antibody for use in the diagnosis of viral infections, viral infectious diseases, B-cell-dependent diseases and/or tumors.

[0325] Preferably, the antibody can be an antibody for use in the therapy, i.e. treatment and/or prevention, of diseases.

[0326] Particularly preferably, the antibody is provided for use in the therapy, i.e. treatment and/or prevention, of viral infections, viral infectious diseases, B-cell-dependent diseases and/or tumors. In other words, the antibody, according to a particularly preferred embodiment, is an antibody for use in the therapy, i.e. treatment and/or prevention, of viral infections, viral infectious diseases, B-cell-dependent diseases and/or tumors.

[0327] The tumors can in principle be benign tumors or malignant tumors.

[0328] Preferably, the tumors are malignant tumors. The malignant tumors can in this case be selected, in particular, from the group consisting of carcinomas, melanomas, plastomas, lymphomas and sarcomas.

[0329] The carcinomas can be selected from the group consisting of anal carcinoma, bronchial carcinoma, pulmonary carcinoma, endometrial carcinoma, gall bladder carcinoma, hepatocellular carcinoma, scrotal carcinoma, colorectal carcinoma, laryngeal carcinoma, esophageal cancer, stomach cancer, breast cancer, renal carcinoma, ovarian cancer, tumor of the pancreas, pharyngeal carcinoma, carcinoma of the prostate, thyroid carcinoma and cervical carcinoma.

[0330] The sarcomas can be selected from the group consisting of angiosarcoma, chondrosarcoma, Ewing sarcoma, fibrosarcoma, Kaposi's sarcoma, liposarcoma, leiomyosarcoma, malign fibrous histiocytoma, neurogenic sarcoma, osteosarcoma and rhabdomyosarcoma.

[0331] With respect to further features and advantages of the antibody, in particular of possible viral infections, viral infectious diseases and/or B-cell-dependent diseases, for the diagnosis and/or therapy of which the antibody can be applied or used, to avoid unnecessary repetition, likewise reference is made in its entirety to the description hereinbefore.

[0332] According to a further aspect, the present invention relates to a further antibody directed against CEACAM1 (anti-CEACAM1 antibody).

[0333] The antibody is distinguished particularly in that it comprises a variable antibody heavy chain (V.sub.H) domain which is encoded by a nucleotide sequence that is selected from the group consisting of SEQ ID No. 4, SEQ ID No. 8 and SEQ ID No. 12, and/or a variable antibody light chain (VL) domain which is encoded by a nucleotide sequence that is selected from the group consisting of SEQ ID No. 6, SEQ ID No. 10 and SEQ ID No. 14.

[0334] Particularly preferably, the antibody comprises a variable antibody heavy chain (V.sub.H) domain which is encoded by a nucleotide sequence as per SEQ ID No. 4, and a variable antibody light chain (V.sub.L) domain which is encoded by a nucleotide sequence as per SEQ ID No. 6.

[0335] In an alternative embodiment, the antibody comprises a variable antibody heavy chain (V.sub.H) domain which is encoded by a nucleotide sequence as per SEQ ID No. 8 and a variable antibody light chain (V.sub.L) domain which is encoded by a nucleotide sequence as per SEQ ID No. 10.

[0336] In a further alternative embodiment, the antibody comprises a variable antibody heavy chain (V.sub.H) domain which is encoded by a nucleotide sequence as per SEQ ID No. 12, and a variable antibody light chain (V.sub.L) domain which is encoded by a nucleotide sequence as per SEQ ID No. 14.

[0337] The antibody, in a preferred embodiment, is a murine antibody or leporine antibody. In other words, it is preferred according to the present invention when the antibody is a mouse antibody, rat antibody or rabbit antibody, i.e. an antibody which has been produced by a mouse, a rat or a rabbit.

[0338] In particular, the variable antibody heavy chain (V.sub.H) domain can be selected from the group consisting of variable antibody heavy chain (V.sub.H) domain of murine origin and variable antibody heavy chain (V.sub.H) domain of leporine origin. In other words, according to the present invention it can be provided, in particular, that the variable antibody heavy chain (V.sub.H) domain has been produced by a mouse, a rat or a rabbit.

[0339] In addition, in particular the variable antibody light chain (V.sub.L) domain can be selected from the group consisting of variable antibody light chain (V.sub.L) domain of murine origin and variable antibody light chain (V.sub.L) domain of leporine origin. In other words, according to the present invention it can be provided, in particular, that the variable antibody light chain (V.sub.L) domain has been produced by a mouse, a rat or a rabbit.

[0340] To improve the compatibility of the antibody, in a further embodiment it can be provided that the antibody comprises a constant antibody heavy chain (C.sub.H) domain of human origin and/or a constant antibody light chain (CO domain of human origin.

[0341] According to a further embodiment, the antibody is a humanized antibody. In this embodiment, the constant antibody heavy chain (C.sub.H) domain and also the constant antibody light chain (CO domain of the antibody are in each case of human origin, whereas the variable antibody heavy chain (V.sub.H) domain and variable antibody light chain (V.sub.L) domain of the antibody are in each case of xenogenic origin, in particular of murine or leporine origin.

[0342] In addition, the antibody is preferably a monoclonal antibody.

[0343] The antibody can in particular be an antibody that is produced by a B cell hybridoma line (B cell clone) that is selected from the group consisting of 6G5J, B3-17 and 18-20.

[0344] The antibody is in addition preferably an antibody for application in medicine.

[0345] In principle, the antibody can be a diagnostic and/or therapeutic antibody. Correspondingly, the antibody can be provided for application in the diagnosis and/or therapy, i.e. treatment and/or prevention, of diseases.

[0346] In principle, the antibody can be an antibody for application in the diagnosis of viral infections, viral infectious diseases, B-cell-dependent diseases and/or tumors.

[0347] Preferably, the antibody is an antibody for application in the therapy, i.e. treatment and/or prevention, of diseases.

[0348] Particularly preferably, the antibody is provided for application in the therapy, i.e. treatment and/or prevention, of viral infections, viral infectious diseases, B-cell-dependent diseases and/or tumors. In other words, the antibody, according to a particularly preferred embodiment, is an antibody for application in the therapy, i.e. treatment and/or prevention, of viral infections, viral infectious diseases, B-cell-dependent diseases and/or tumors.

[0349] With respect to further features and advantages of the antibody, in particular of possible viral infections, viral infectious diseases, B-cell-dependent diseases and/or tumors, for the diagnosis and/or therapy of which the antibody can be used or applied, to avoid unnecessary repetition, likewise reference is made in its entirety to the description hereinbefore.

[0350] According to a further aspect, the present invention relates to a variable antibody heavy chain (V.sub.H) domain of an antibody directed against CEACAM1 (anti-CEACAM1 antibody).

[0351] The variable antibody heavy chain (V.sub.H) domain is selected from the group consisting of antibody heavy chain (V.sub.H) domain as per SEQ ID No. 3, variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 7 and variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 11.

[0352] The variable antibody heavy chain (V.sub.H) domain, in a preferred embodiment, is of murine or leporine origin. In other words, it is preferred according to the present invention when the variable antibody heavy chain (V.sub.H) domain has been produced by a mouse, a rat or a rabbit.

[0353] The antibody is preferably a monoclonal antibody.

[0354] With respect to further features and advantages of the variable antibody heavy chain (V.sub.H) domain, and also of the antibody, to avoid unnecessary repetition, likewise reference is made in its entirety to the description hereinbefore. The embodiments and also advantages in respect of the variable antibody heavy chain (V.sub.H) domain and also the antibody also apply accordingly to the variable antibody heavy chain (V.sub.H) domain according to the eighth aspect of the present invention.

[0355] According to a further aspect, the present invention relates to a variable antibody light chain (V.sub.L) domain of an antibody directed against CEACAM1 (anti-CEACAM1 antibody).

[0356] The variable antibody light chain (V.sub.L) domain is selected from the group consisting of variable antibody light chain (V.sub.L) domain as per SEQ ID No. 5, variable antibody light chain (V.sub.L) domain as per SEQ ID No. 9 and variable antibody light chain (V.sub.L) domain as per SEQ ID No. 13.

[0357] The variable antibody light chain (V.sub.L) domain, in a preferred embodiment, is of murine or leporine origin. In other words, it is preferred according to the present invention when the variable antibody light chain (V.sub.L) domain has been produced by a mouse, a rat or a rabbit.

[0358] The antibody is preferably a monoclonal antibody.

[0359] With respect to further features and advantages of the variable antibody light chain (V.sub.L) domain and also of the antibody, to avoid unnecessary repetition, likewise reference is made in its entirety to the description hereinbefore. The embodiments and advantages described there in relation to the variable antibody light chain (V.sub.L) domain and the antibody also apply accordingly to the variable antibody light chain (V.sub.L) domain according to the ninth aspect of the present invention.

[0360] According to a further aspect, the present invention relates to an isolated nucleic acid which encodes a variable antibody heavy chain (V.sub.H) domain of an antibody directed against CEACAM1 (anti-CEACAM1 antibody).

[0361] The nucleic acid and also the antibody are preferably a human nucleic acid or human antibody. The antibody is preferably a monoclonal antibody.

[0362] The nucleic acid comprises a nucleotide sequence or consists of a nucleotide sequence that is selected from the group consisting of SEQ ID No. 4 and SEQ ID No. 8 and SEQ ID No. 12.

[0363] With respect to further features and advantages of the nucleic acid, to avoid unnecessary repetition, likewise reference is made in its entirety to the description given before. The embodiments and advantages described there in particular in relation to the variable antibody heavy chain (V.sub.H) domain and the antibody also apply correspondingly to the nucleic acid according to the tenth aspect of the present invention.

[0364] According to a further aspect, the present invention relates to an isolated nucleic acid which encodes a variable antibody light chain (V.sub.L) domain of an antibody directed against CEACAM1 (anti-CEACAM1 antibody).

[0365] The nucleic acid and also the antibody are preferably a human nucleic acid and/or human antibody. The antibody is preferably a monoclonal antibody.

[0366] The nucleic acid comprises a nucleotide sequence or consists of a nucleotide sequence which is selected from the group consisting of SEQ ID No. 6, SEQ ID No. 10 and SEQ ID No. 14.

[0367] With respect to further features and advantages of the nucleic acid, to avoid unnecessary repetition, likewise reference is made in its entirety to the description hereinbefore. The embodiments and advantages described there in particular in relation to the variable antibody light chain (V.sub.L) domain and also the antibody also apply correspondingly to the nucleic acid according to the eleventh aspect of the present invention.

[0368] According to a further aspect, the present invention relates to a hybridoma cell which produces an antibody according to an abovementioned aspect of the present invention.

[0369] The hybridoma cell is preferably formed by fusion of B-lymphocytes, which originate from an experimental animal immunized against CEACAM1 and produce antibodies directed against CEACAM1 (anti-CEACAM1 antibodies), and myeloma cells. The experimental animal can be selected from the group consisting of mouse, rat, rabbit and goat. Myeloma cells are taken to mean in general cells (plasma cells) of a cell line obtained from a myeloma (plasmacytoma) of an animal. The myeloma cells can be obtained in the context of the present invention from the myeloma of a mouse, a rat, a rabbit or a goat.

[0370] Preferably, the myeloma cells are cells from the mouse myeloma cell line NS1/0.

[0371] The hybridoma cell preferably belongs to a B cell hybridoma line (B cell clone) that is selected from the group consisting of 6G5J, B3-17 and 18-20.

[0372] With regard to further features and advantages of the hybridoma cell, to avoid unnecessary repetition, likewise reference is made in its entirety to the description hereinbefore. The embodiments and advantages described there in particular with respect to the antibody apply correspondingly also to the hybridoma cell according to the twelfth aspect of the present invention.

[0373] According to a further aspect, the present invention relates to a method for producing an antibody directed against CEACAM1 (anti-CEACAM1 antibody), in particular an antibody according to the sixth or seventh aspect of the present invention.

[0374] The method has the following steps: [0375] (a) fusing B cells which originate from an experimental animal immunized against an antigen, and myeloma cells, forming hybridoma cells, [0376] (b) selecting the hybridoma cells, [0377] (c) isolating hybridoma cells that produce antibodies directed against the antigen.

[0378] As compared with methods of the type in question, the method according to the present invention is particularly distinguished in that the antigen is selected from the group consisting of CEACAM1 as per SEQ ID No. 1, CEACAM1 as per SEQ ID No. 2 (therefore the expression product of SEQ ID No. 1 or 2) and/or CEACAM1 as per SEQ ID No. 43, a fragment, in particular epitope, of SEQ ID No. 1 and a fragment, in particular epitope, of SEQ ID No. 2 (therefore the expression product of SEQ ID No. 1 or 2) and/or SEQ ID No. 43.

[0379] In a preferred embodiment, the antigen is CEACAM1 as per SEQ ID No. 1 (therefore the expression product of SEQ ID No. 1) and/or CEACAM1 as per SEQ ID No. 43 or a fragment, in particular epitope, thereof.

[0380] In an alternative embodiment, the antigen is CEACAM1 as per SEQ ID No. 2 (therefore the expression product of SEQ ID No. 2) or a fragment, in particular epitope, thereof.

[0381] The experimental animal, in a preferred embodiment, is a mouse, a rat, a rabbit or a goat. The use of a mouse as an experimental animal, however, is particularly preferred according to the present invention.

[0382] The B cells can be fused with cells from a cell line obtained from a myeloma of a mouse, a rat, a rabbit or a goat.

[0383] Preferably, the B cells are fused with cells of the mouse myeloma cell line NS1/0.

[0384] The step a), that is to say the cell fusion, can be carried out using polyethylene glycol (PEG). For this purpose, the B cells and myeloma cells are added together into an aqueous polyethylene glycol-containing fusion solution and centrifuged. Since the water is substantially bound by PEG, the cell membranes are brought together in close contact, as a result of which spontaneous fusion of the cell membranes is achieved.

[0385] Alternatively, step a) can be performed under the action of electrical voltage, i.e. as what is termed electrofusion. During the electrofusion, by means of electrical pulses, the cell membranes are melted locally, as a result of which a coalescence of the cell membranes is achieved. In order to support the fusion, small amounts of PEG can be added.

[0386] The B cells and the myeloma cells are, in a further embodiment, fused in a ratio of 5:1 (B cells to myeloma cells).

[0387] Step b) in a preferred embodiment is carried out using a selective medium, in which only hybridoma cells are capable of surviving. As a selective medium, preferably, what is termed HAT medium is used. The HAT medium contains the chemical substances hypoxanthine, aminopterine and thymidine. Hypoxanthine is a precursor for essential molecules (purines) that are required for the buildup of deoxyribonucleic acid (DNA). For the conversion thereof, however, the enzyme hypoxanthine-guanine phosphoribosyl transferase (HGPRT) is necessary. Since, in the fusion a myeloma cell line is used, from which precisely this enzyme is missing or is present in inactive form, individual myeloma cells are therefore not capable of survival in this medium. Spleen cells, in contrast, possess HGPRT, but are not themselves capable of survival, and rapidly die off in the culture medium. Only hybridoma cells can be cultured, since they possess the immortality of the myeloma cells and also the HGPRT genes of the spleen cells. Aminopterine serves only for blocking other purine synthesis pathways. Since, as a result, the essential thymidine can no longer be produced de novo, it must be added to the medium.

[0388] Step c) is preferably carried out by means of ELISA (Enzyme-linked immunosorbant assay) test or by continuous-flow cytometry.

[0389] In a further embodiment, the isolated hybridoma cells are expanded. This ensures that a sufficiently large number of hybridoma cells are available that produce the antibody directed against CEACAM1 (anti-CEACAM1 antibody).

[0390] With respect to further features and advantages of the method, in particular the hybridoma cells, the antigen and also the antibody, reference is made in its entirety to the details given hereinbefore and also in the example section. The embodiments and advantages described there in particular in respect of the hybridoma cell, the antigen and also the antibody, also apply correspondingly to the method as per the thirteenth aspect of the present invention.

[0391] The other sequences shown in the present application are as follows:

TABLE-US-00003 SEQIDNo.1:humanCEACAM1(Hu-CEACAM1+ Hu-IgG-Fc2)(Homosapiens): CAGCTGACCACCGAGAGCATGCCCTTCAACGTGGCCGAGGGCAAGGAG GTGCTGCTGCTGGTGCACAACCTGCCCCAGCAGCTGTTCGGCTACAGCTG GTACAAGGGCGAGAGGGTGGACGGCAACAGGCAGATCGTGGGCTACGCCA TCGGCACCCAGCAGGCCACCCCCGGCCCCGCCAACAGCGGCAGGGAGACC ATCTACCCCAACGCCAGCCTGCTGATCCAGAACGTGACCCAGAACGACAC CGGCTTCTACACCCTGCAGGTGATCAAGAGCGACCTGGTGAACGAGGAGG CCACCGGCCAGTTCCACGTGTACCCCGAGCTGCCCAAGCCCAGCATCAGC AGCAACAACAGCAACCCCGTGGAGGACAAGGACGCCGTGGCCTTCACCTG CGAGCCCGAGACCCAGGACACCACCTACCTGTGGTGGATCAACAACCAGA GCCTGCCCGTGAGCCCCAGGCTGCAGCTGAGCAACGGCAACAGGACCCTG ACCCTGCTGAGCGTGACCAGGAACGACACCGGCCCCTACGAGTGCGAGAT CCAGAACCCCGTGAGCGCCAACAGGAGCGACCCCGTGACCCTGAACGTGA CCTACGGCCCCGACACCCCCACCATCAGCCCCAGCGACACCTACTACAGG CCCGGCGCCAACCTGAGCCTGAGCTGCTACGCCGCCAGCAACCCCCCCGC CCAGTACAGCTGGCTGATCAACGGCACCTTCCAGCAGAGCACCCAGGAGC TGTTCATCCCCAACATCACCGTGAACAACAGCGGCAGCTACACCTGCCAC GCCAACAACAGCGTGACCGGCTGCAACAGGACCACCGTGAAGACCATCAT CGTGACCGAGCTGAGCCCCGTGGTGGCCAAGCCCCAGATCAAGGCCAGCA AGACCACCGTGACCGGCGACAAGGACAGCGTGAACCTGACCTGCAGCACC AACGACACCGGCATCAGCATCAGGTGGTTCTTCAAGAACCAGAGCCTGCC CAGCAGCGAGAGGATGAAGCTGAGCCAGGGCAACACCACCCTGAGCATCA ACCCCGTGAAGAGGGAGGACGCCGGCACCTACTGGTGCGAGGTGTTCAAC CCCATCAGCAAGAACCAGAGCGACCCCATCATGCTGAACGTGGAGTGCCC ACCTTGCCCAGCACCACCTGTGGCAGGACCTTCAGTCTTCCTCTTCCCCC CAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGC AGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG GACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCT CCCATCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAG AACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAAC CAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGC CGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGC CTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACC GTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGAT GCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTC CGGGTAAA SEQIDNo.2:humanCEACAM1(IL2Secretory sequence+ Hu-CEACAM1+ Hu-IgG-Fc2) (Homosapiens): CCTGAGATCACCGGCGAAGGAGGGCCACCATGTACAGGATGCAACTCC TGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGCAGCTGACC ACCGAGAGCATGCCCTTCAACGTGGCCGAGGGCAAGGAGGTGCTGCTGCT GGTGCACAACCTGCCCCAGCAGCTGTTCGGCTACAGCTGGTACAAGGGCG AGAGGGTGGACGGCAACAGGCAGATCGTGGGCTACGCCATCGGCACCCAG CAGGCCACCCCCGGCCCCGCCAACAGCGGCAGGGAGACCATCTACCCCAA CGCCAGCCTGCTGATCCAGAACGTGACCCAGAACGACACCGGCTTCTACA CCCTGCAGGTGATCAAGAGCGACCTGGTGAACGAGGAGGCCACCGGCCAG TTCCACGTGTACCCCGAGCTGCCCAAGCCCAGCATCAGCAGCAACAACAG CAACCCCGTGGAGGACAAGGACGCCGTGGCCTTCACCTGCGAGCCCGAGA CCCAGGACACCACCTACCTGTGGTGGATCAACAACCAGAGCCTGCCCGTG AGCCCCAGGCTGCAGCTGAGCAACGGCAACAGGACCCTGACCCTGCTGAG CGTGACCAGGAACGACACCGGCCCCTACGAGTGCGAGATCCAGAACCCCG TGAGCGCCAACAGGAGCGACCCCGTGACCCTGAACGTGACCTACGGCCCC GACACCCCCACCATCAGCCCCAGCGACACCTACTACAGGCCCGGCGCCAA CCTGAGCCTGAGCTGCTACGCCGCCAGCAACCCCCCCGCCCAGTACAGCT GGCTGATCAACGGCACCTTCCAGCAGAGCACCCAGGAGCTGTTCATCCCC AACATCACCGTGAACAACAGCGGCAGCTACACCTGCCACGCCAACAACAG CGTGACCGGCTGCAACAGGACCACCGTGAAGACCATCATCGTGACCGAGC TGAGCCCCGTGGTGGCCAAGCCCCAGATCAAGGCCAGCAAGACCACCGTG ACCGGCGACAAGGACAGCGTGAACCTGACCTGCAGCACCAACGACACCGG CATCAGCATCAGGTGGTTCTTCAAGAACCAGAGCCTGCCCAGCAGCGAGA GGATGAAGCTGAGCCAGGGCAACACCACCCTGAGCATCAACCCCGTGAAG AGGGAGGACGCCGGCACCTACTGGTGCGAGGTGTTCAACCCCATCAGCAA GAACCAGAGCGACCCCATCATGCTGAACGTGGAGTGCCCACCTTGCCCAG CACCACCTGTGGCAGGACCTTCAGTCTTCCTCTTCCCCCCAAAACCCAAG GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGA CGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGC ACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAA TGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCATCCTCCA TCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTG TACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCT GACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGG AGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTG GACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAG CAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTC TGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA SEQIDNo.3:anti-humanCEACAM1antibody (clone6G5J)-heavychain(V-D-J-REGION) (Musmusculus): KPGETVKISCKTSGYIFRNYGMKWVKQAPGKGLKWMGWINTYTGEPTY ADDFKGRFAFSLETSASTAYLQINNLKNEDMATYFCARRGMITTSNYALD NWGQGTSVTVSS SEQIDNo.4:anti-humanCEACAM1antibody (clone6G5J)-heavychain(V-D-J-REGION) (Musmusculus): aagcctggagagacagtcaagatctcctgcaagacttctg ggtatatattcagaaactatggaatgaaatgggtgaagca ggctccaggaaagggtttaaagtggatgggctggataaac acctatactggagagccaacatatgctgatgacttcaagg gacggtttgccttctctttggaaacctctgccagcactgc ctatttgcagatcaacaacctcaaaaatgaggacatggct acatatttctgtgcaagaagggggatgattacgacgagta attatgctctggacaactggggtcaaggaacctcagtcac cgtctcctcag SEQIDNo.5:anti-humanCEACAM1antibody (clone6G5J)-lightchain(V-J-REGION) (Musmusculus): SSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTIKLLIYYTSKLHSGV PSRFSGSGSGTDYSLTISNLDQEDIATYFCQQGNTLPWTFGGGTKLEIK SEQIDNo.6:anti-humanCEACAM1antibody (clone6G5J)-lightchain(V-J-REGION) (Musmusculus): tcctccctgtctgcctctctgggagacagagtcaccatca gttgcagggcaagtcaggacattagcaattatttaaactg gtatcagcagaaaccagatggaactattaaactcctgatc tactacacatcaaagttacactcaggagtcccatcaagat tcagtggcagtgggtctggaacagattattctctcaccat tagcaacctggaccaggaagatattgccacttacttttgc caacagggtaatactcttccgtggacgttcggtggaggca ccaagctggaaatcaaac SEQIDNo.7:anti-humanCEACAM1antibody (clone18-20)-heavychain(V-D-JRegion) (Musmusculus): KPGETVKISCKASGYTFTVYGMNWVKQAPGKDLKWMGWINTYTGEPTY ADDFKGRFAFSLETSASTAYLQINNLKNEDMATYFCARKAFYRYDGGMDY WGQGTSVTVSS SEQIDNo.8:anti-humanCEACAM1antibody (clone18-20)-heavychain(V-D-JRegion) (Musmusculus): aagcctggagagacagtcaagatctcctgcaaggcttctg ggtataccttcacagtctatggaatgaactgggtgaagca ggctccaggaaaggatttaaagtggatgggctggataaac acctacactggagagccaacatatgctgatgacttcaagg gacggtttgccttctctttggaaacctctgccagcactgc ctatttgcagatcaacaacctcaaaaatgaggacatggct acatatttctgtgcaagaaaggccttctataggtacgacg ggggtatggactactggggtcaaggaacctcagtcaccgt ctcctcag SEQIDNo.9:anti-humanCEACAM1antibody (clone18-20)-lightchain(V-J-Region) (Musmusculus): SSLSASLGGKVTITCKASQDINKFLAWYQHKPGKGPRLLIHYTSTLQPGI PSRFSGSGSGRDYSFSISNLEPEDIATYYCLQYDNLYTFGGGTKLEIK SEQIDNo.10:anti-humanCEACAM1antibody (clone18-20)-lightchain(V-J-Region) (Musmusculus): tcctcactgtctgcatctctgggaggcaaagtcaccatca cttgcaaggcaagccaagacattaacaagtttttagcttg gtaccaacacaagcctggaaaaggtcctaggctgctcata cattacacatctacattacagccaggcatcccatcaaggt tcagtggaagtgggtctgggagagattattccttcagcat cagcaacctggagcctgaagatattgcaacttattattgt ctacaatatgataatctgtacacgttcggtggggggacca agctggaaataaaac SEQIDNo.11:anti-humanCEACAM1antibody (cloneB3-17)-heavychain(V-D-J-REGION) (Musmusculus): GPELVKPGTSVKMSCKASGYTFTTYVMHWVQQKPGQGLDWIGFFNPYN DGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARWAYDGSY AYWGQGTTLTVSS SEQIDNo.12:anti-humanCEACAM1antibody (cloneB3-17)-heavychain(V-D-J-REGION) (MusMusculus): ggacctgagctggtaaagcctgggacttcagtgaagatgt cctgcaaggcttctggatacacattcactacctatgttat gcactgggtgcaacagaagcctgggcagggccttgactgg attggattttttaatccttacaatgatggtactaagtaca atgagaagttcaaaggcaaggccacactgacttcagacaa atcctccagcacagcctacatggaactcagcagcctgacc tctgaggactctgcggtctattactgtgcaagatgggcct acgatggtagctacgcctactggggccaaggcaccactct cacagtctcctcag SEQIDNo.13:anti-humanCEACAM1antibody (cloneB3-17)-lightchain(V-J-REGION) (Musmusculus): SYLSVFLGGRVTITCKASDHINNWLAWYQQKPGNAPRLLISGATSLETGV PSRFSGSGSGKDYTLSIISLQTEDVATYYCQQYWRTPFTFGSGTKLEIK SEQIDNo.14:anti-humanCEACAM1antibody (cloneB3-17)-lightchain(V-J-REGION) (Musmusculus): tcctacttgtctgtatttctaggaggcagagtcaccatta cttgcaaggcaagtgaccacattaataattggttagcctg gtatcagcagaaaccaggaaatgctcctaggctcttaata tctggggcaaccagtttggaaactggggttccttcaagat tcagtggcagtggatctggaaaggattacactctcagcat tatcagtcttcagactgaagatgttgctacttattactgt caacagtattggagaactccattcacgttcggctcgggga caaagttggaaataaaac SEQIDNo.15:solubleUspA1(Moraxella catarhalis)GenBank:U61725.1: MNKIYKVKKNAAGHLVACSEFAKGHTKKAVLGSLLIVGALGMATTASAQ ATKGTGKHVVDNKDNKAKGDYSTASGGKDNEAKGNYSTVGGGDYNEAKGN YSTVGGGSSNTAKGEKSTIGGGDTNDANGTYSTIGGGYYSRAIGDSSTIG GGYYNQATGEKSTVAGGRNNQATGNNSTVAGGSYNQATGNNSTVAGGSHN QATGEGSFAAGVENKANANNAVALGKNNTIDGDNSVAIGSNNTIDSGKQN VFILGSSTNTTNAQSGSVLLGHNTAGKKATAVSSAKVNGLTLGNFAGASK TGNGTVSVGSENNERQIVNVGAGNISADSTDAVNGSQLYALATAVKADAD ENFKALTKTQNTLIEQGEAQDALIAQNQTDITANKTAIERNFNRTVVNGF EIEKNKAGIAKNQADIQTLENNVGEELLNLSGRLLDQKADIDNNINNIYD LAQQQDQHSSDIKTLKKNVEEGLLDLSGRLIDQKADLTKDIKTLENNVEE GLLDLSGRLIDQKADIAKNQADIAQNQTDIQDLAAYNELQDQYAQKQTEA IDALNKASSANTDRIATAELGIAENKKDAQIAKAQANENKDGIAKNQADI QLHDKKITNLGILHSMVARAVGNNTQGVATNKADIAKNQADIANNIKNIY ELAQQQDQHSSDIKTLAKVSAANTDRIAKNKAEADASFETLTKNQNTLIE QGEALVEQNKAINQELEGFAAHADVQDKQILQNQADITTNKAAIEQNINR TVANGFEIEKNKAGIATNKQELILQNDRLNQINETNNRQDQKIDQLGYAL KEQGQHFNNRISAVERQTAGGIANAIAIATLPSPSRAGEHHVLFGSGYHN GQAAVSLGAAGLSDTGKSTYKIGLSWSDAGGLSGGVGGSYRWK SEQIDNo.16:solubleUspA1(Moraxella catarhalis)GenBank:U61725.1: tgtgagcaaatgactggcgtaaatgactgatgaatgtcta tttaatgaaagatatcaatatataaaagttgactatagcg atgcaatacagtaaaatttgttacggctaaacataacgac ggtccaagatggcggatatcgccatttaccaacctgataa tcagtttgatagccattagcgatggcatcaagttgtgttg ttgtattgtcatataaacggtaaatttggtttggtggatg ccccatctgatttaccgtccccctaataagtgaggggggg ggagaccccagtcatttattaggagactaagatgaacaaa atttataaagtgaaaaaaaatgccgcaggtcacttggtgg catgttctgaatttgccaaaggccataccaaaaaggcagt tttgggcagtttattgattgttggggcattgggcatggca acgacggcgtctgcacaagcaaccaaaggcacaggcaagc acgttgttgacaataaggacaacaaagccaaaggcgatta ctctaccgccagtggtggcaaggacaacgaagccaaaggc aattactctaccgtcggtggtggcgattataacgaagcca aaggcaattactctaccgtcggtggtggctctagtaatac cgccaaaggcgagaaatcaaccatcggtggtggcgatact aacgacgccaacggcacatactctaccatcggtggtggct attatagccgagccataggcgatagctctaccatcggtgg tggttattataaccaagccacaggcgagaaatcaacggtt gcagggggcaggaataaccaagccacaggcaacaactcaa cggttgcaggcggctcttataaccaagccacaggcaacaa ctcaacggttgcaggtggctctcataaccaagccacaggt gaaggttcatttgcagcaggtgtagagaacaaagccaatg ccaacaacgccgtcgctctaggtaaaaataacaccatcga tggcgataactcagtagccatcggctctaataataccatt gacagtggcaaacaaaatgtctttattcttggctctagca caaacacaacaaatgcacaaagcggctccgtgctgctggg tcataataccgctggcaaaaaagcaaccgctgttagcagt gccaaagtgaacggcttaaccctaggaaattttgcaggtg catcaaaaactggtaatggtactgtatctgtcggtagtga gaataatgagcgtcaaatcgtcaatgttggtgcaggtaat atcagtgctgattcaacagatgctgttaatggctcacagc tatatgctttggccacagctgtcaaagccgatgccgatga aaactttaaagcactcaccaaaactcaaaatactttgatt gagcaaggtgaagcacaagacgcattaatcgctcaaaatc aaactgacatcactgccaataaaactgccattgagcgaaa ttttaatagaactgttgtcaatgggtttgagattgagaaa aataaagctggtattgctaaaaaccaagcggatatccaaa cgcttgaaaacaatgtcggagaagaactattaaatctaag cggtcgcctgcttgatcaaaaagcggatattgataataac atcaacaatatctatgatctggcacaacagcaagatcagc atagctctgatatcaaaacacttaaaaaaaatgtcgaaga aggtttgttggatctaagtggtcgcctcattgatcaaaaa gcagatcttacgaaagacatcaaaacacttgaaaacaatg tcgaagaaggtttgttggatctaagcggtcgcctcattga tcaaaaagcagatattgctaaaaaccaagctgacattgct caaaaccaaacagacatccaagatctggccgcttacaacg agctacaagaccagtatgctcaaaagcaaaccgaagcgat tgacgctctaaataaagcaagctctgccaatactgatcgt attgctactgctgaattgggtatcgctgagaacaaaaaag acgctcagatcgccaaagcacaagccaatgaaaataaaga cggcattgctaaaaaccaagctgatatccagttgcacgat aaaaaaatcaccaatctaggtatccttcacagcatggttg caagagcggtaggaaataacacacaaggtgttgctaccaa taaagctgacattgctaaaaaccaagcagatattgctaat aacatcaaaaatatctatgagctggcacaacagcaagatc agcatagctctgatatcaaaaccttggcaaaagtaagtgc tgccaatactgatcgtattgctaaaaacaaagctgaagct gatgcaagttttgaaacgctcaccaaaaatcaaaatactt tgattgagcaaggtgaagcattggttgagcaaaataaagc catcaatcaagagcttgaagggtttgcggctcatgcagat gttcaagataagcaaattttacaaaaccaagctgatatca ctaccaataaggccgctattgaacaaaatatcaatagaac tgttgccaatgggtttgagattgagaaaaataaagctggt attgctaccaataagcaagagcttattcttcaaaatgatc gattaaatcaaattaatgagacaaataatcgtcaggatca gaagattgatcaattaggttatgcactaaaagagcagggt cagcattttaataatcgtattagtgctgttgagcgtcaaa cagctggaggtattgcaaatgctatcgcaattgcaacttt accatcgcccagtagagcaggtgagcatcatgtcttattt ggttcaggttatcacaatggtcaagctgcggtatcattgg gtgcggctgggttaagtgatacaggaaaatcaacttataa gattggtctaagctggtcagatgcaggtggattatctggt ggtgttggtggcagttaccgctggaaatagagcctaaatt taactgctgtatcaaaaaatatggtctgtataaacagacc atatttttatctaaaaacttatcttaacttttatgaagca tcataagccaaagctgagtaataataagagatgttaaaat aagagatgttaaaactgctaaacaatcggcttacgacgat aaaataaaatacctggaatggacagccccaaaaccaatgc tgagatgataaaaatcgcctcaaaaaaatgacgcatcata acgataaataaatccatatcaaatccaaaatagccaattt gtaccatgctaaccatggctttataggcagcgattcccgg catcatacaaatcaagctaggtacaatcaaggctttaggc ggcaggccatgacgctgagca SEQIDNo.17:solubleOpa(Neisseria gonorrhoeae)UniProtKB/Swiss-Prot: Q0PS02_NEIME: YAAERITHDYPKATGANNTSTVSDYFRNIRAHSIHPRVSVGYDFGGWRIA ADYASYRKWKESNSSTNAENRDSIQNYVKIETKHQGNGSFHAASSLGLSA IYDFKLNDKFKPYIGARVAYGHVKHQVHSVESKNTIITSKPTGNTPAGGP VPTGFVPKSAYHESHSISSL SEQIDNo.18:OutermembraneproteinP5 (Haemophilusinfluenzae)UniProtKB/Swiss- Prot:P43840.1: MKKTAIALVVAGLAAASVAQAAPQENTFYAGVKAGQASFHDGLRALARE YKVGYHRNSFTYGVFGGYQILNQNNLGLAVELGYDDFGRAKGREKGKTVV KHTNHGTHLSLKGSYEVLEGLDVYGKAGVALVRSDYKLYNENSSTLKKLG EHHRARASGLFAVGAEYAVLPELAVRLEYQWLTRVGKYRPQDKPNTALNY NPWIGSINAGISYRFGQGAAPVVAAPEVVSKTFSLNSDVTFAFGKANLKP QAQATLDSIYGEMSQVKSAKVAVAGYTDRIGSDAFNVKLSQERADSVANY FVAKGVAADAISATGYGKANPVTGATCDQVKGRKALIACFAPDRRVEIAV NGTK SEQIDNo.19:solublehumanrecombinantCEACAM1 fusionprotein(humanCEACAM1(ENSG00000079385) withIL-2SecretoryLeader sequenceandhuman IgG-Fc2fusionprotein): PEITGEGGPPCTGCNSCLALHVLHLSRIRQLTTESMPFNVAEGKEVLLLV HNLPQQLFGYSWYKGERVDGNRQIVGYAIGTQQATPGPANSGRETIYPNA SLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSN PVEDKDAVAFTCEPETQDTTYLWWINNQSLPVSPRLQLSNGNRTLTLLSV TRNDTGPYECEIQNPVSANRSDPVTLNVTYGPDTPTISPSDTYYRPGANL SLSCYAASNPPAQYSWLINGTFQQSTQELFIPNITVNNSGSYTCHANNSV TGCNRTTVKTIIVTELSPVVAKPQIKASKTTVTGDKDSVNLTCSTNDTGI SIRWFFKNQSLPSSERMKLSQGNTTLSINPVKREDAGTYWCEVFNPISKN QSDPIMLNVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQIDNo.20:solublehumanrecombinantCEACAM1 fusionprotein(humanCEACAM1(ENSG00000079385) withIL-2SecretoryLeader sequenceandhuman IgG-Fc2fusionprotein): cctgagatcaccggcgaaggagggccaccatgtacaggat gcaactcctgtcttgcattgcactaagtcttgcacttgtc acgaattcgcagctgaccaccgagagcatgcccttcaacg tggccgagggcaaggaggtgctgctgctggtgcacaacct gccccagcagctgttcggctacagctggtacaagggcgag agggtggacggcaacaggcagatcgtgggctacgccatcg gcacccagcaggccacccccggccccgccaacagcggcag ggagaccatctaccccaacgccagcctgctgatccagaac gtgacccagaacgacaccggcttctacaccctgcaggtga tcaagagcgacctggtgaacgaggaggccaccggccagtt ccacgtgtaccccgagctgcccaagcccagcatcagcagc aacaacagcaaccccgtggaggacaaggacgccgtggcct tcacctgcgagcccgagacccaggacaccacctacctgtg gtggatcaacaaccagagcctgcccgtgagccccaggctg cagctgagcaacggcaacaggaccctgaccctgctgagcg tgaccaggaacgacaccggcccctacgagtgcgagatcca gaaccccgtgagcgccaacaggagcgaccccgtgaccctg aacgtgacctacggccccgacacccccaccatcagcccca gcgacacctactacaggcccggcgccaacctgagcctgag ctgctacgccgccagcaacccccccgcccagtacagctgg ctgatcaacggcaccttccagcagagcacccaggagctgt tcatccccaacatcaccgtgaacaacagcggcagctacac ctgccacgccaacaacagcgtgaccggctgcaacaggacc accgtgaagaccatcatcgtgaccgagctgagccccgtgg tggccaagccccagatcaaggccagcaagaccaccgtgac cggcgacaaggacagcgtgaacctgacctgcagcaccaac gacaccggcatcagcatcaggtggttcttcaagaaccaga gcctgcccagcagcgagaggatgaagctgagccagggcaa caccaccctgagcatcaaccccgtgaagagggaggacgcc ggcacctactggtgcgaggtgttcaaccccatcagcaaga accagagcgaccccatcatgctgaacgtggagtgcccacc ttgcccagcaccacctgtggcaggaccttcagtcttcctc ttccccccaaaacccaaggacaccctcatgatctcccgga cccctgaggtcacatgcgtggtggtggacgtgagccacga agaccctgaggtcaagttcaactggtacgtggacggcgtg gaggtgcataatgccaagacaaagccgcgggaggagcagt acaacagcacgtaccgtgtggtcagcgtcctcaccgtcct gcaccaggactggctgaatggcaaggagtacaagtgcaag gtctccaacaaaggcctcccatcctccatcgagaaaacca tctccaaagccaaagggcagccccgagaaccacaggtgta caccctgcccccatcccgggaggagatgaccaagaaccag gtcagcctgacctgcctggtcaaaggcttctatcccagcg acatcgccgtggagtgggagagcaatgggcagccggagaa caactacaagaccacgcctcccgtgctggactccgacggc tccttcttcctctacagcaagctcaccgtggacaagagca ggtggcagcaggggaacgtcttctcatgctccgtgatgca tgaggctctgcacaaccactacacgcagaagagcctctcc ctgtctccgggtaaa

EXAMPLE SECTION

1.1.1 Description and Analysis of the Drawings

[0392] FIG. 1A shows representative continuous-flow cytometry histograms of profilerating B cells of wildtype (WT) or CEACAM1/ mice (CEACAM1-Knockout mice), which were untreated (gray area), treated with anti-CEACAM1 antibody, LPS, or with recombinant mice-CD40 ligand in combination with mouse IL-4 (black line) for 48 hours. DAPI cells are shown (n=6).

[0393] FIG. 1B shows the absolute number of live cells B (DAPI) at stated time points (n=3); sorted from the spleen, after treatment with or without recombinant mouse-CD40 ligand in combination with mouse IL-4 (n=3).

[0394] FIG. 1C shows representative histograms and statistical analysis of Annexin-V+ B cells: which were stimulated with recombinant mouse-CD40 ligand in combination with mouse IL-4 or left unstimulated, after 48 hours (DAPI B cells are shown, n=6).

[0395] FIG. 1D shows the percentage of DAPI+ B cells from the spleen of WT and CEACAM1/ mice after activation with recombinant mouse-CD40 ligand in combination with mouse IL-4 in the presence or absence of Btk inhibitor Ibrutinib cultured for 48 hours determined by FACS analysis (n=6). * P<0.05; ** P<0/01; and *** P<0.001 (Student t-test).

[0396] The results shown graphically in FIGS. 1A to 1D show that CEACAM1 promotes the survival of B cells in vitro.

[0397] FIG. 2A shows a scheme of development, maturation and migration of B cells in bone marrow, blood, lymph nodes and spleen. The continuous arrows show the probable development pathway. The dashed arrows show a development pathway that is still under discussion. The dotted arrows show the differentiation after antigen stimulation. The dash-dot arrow shows assumed development pathways.

[0398] FIGS. 2B-E show the total number of B cell subpopulations of wildtype (WT) and CEACAM1/ mice, measured by means of continuous-flow cytometry in bone marrow (b, n=6), in blood (c, n=4), lymph nodes (d, n=4) and in the spleen (e, n=10). For markers see Methods.

[0399] The results shown graphically in FIGS. 2A to 2D show that the expression of CEACAM1 promotes B cell differentiation and the survival of B cells in vivo.

[0400] FIG. 3 shows the total number of B1a and B2 B cell subpopulations (B1a, CD19lowCD5int; B2, CD19highCD5neg) and T cells of wildtype (WT) and CEACAM1/ mice, measured by means of continuous-flow cytometry in the abdominal cavity (n=6). * P<0.05 (Student t-test); ns=not significant.

[0401] The results shown graphically in FIG. 3 show that the expression of CEACAM1 changes the B1 B cells.

[0402] FIG. 4 shows the amount of serum immunoglobulins in nave wildtype (WT) and CEACAM1/ mice (n=8 per genotype). ** P<0.01; and *** P<0.001 (Student t-test).

[0403] The results shown graphically in FIG. 4 show an advantageous influencing of the serum immunoglobulins by CEACAM1.

[0404] FIG. 5A shows the percentage of WTVi10 B cells and CEACAM1/Vi10 B cells which were transferred adoptively to WT mice (110.sup.7 per mouse) on day 1 and which were infected with 210.sup.6 PFU of vesicular stromatitis virus (VSV) on day 0. Analysis day 3 after infection (n=3).

[0405] FIGS. 5B and C show the total VSV neutralizing antibodies and neutralizing IgG antibodies in WT and CEACAM1/ mice after intravenous infection with 210.sup.6 PFU VSV (B, n=6-9 per group) and/or after the intravenous infection with 210.sup.8 PFU of UV-inactivated VSV (C, n=8-9 per group).

[0406] FIG. 5D shows the VSV-neutralizing antibody response and neutralizing IgG antibodies in the sera of WT and CEACAM1/ mice that had received 110.sup.7 VSV-specific B cells (Vi10) on day 1 and were then infected with 210.sup.6 PFU VSV on day 0 (n=7-9 per group).

[0407] FIG. 5E shows the VSV titer in various organs of WT and CEACAM1/ mice after intravenous infection with 210.sup.6 PFU VSV analyzed 8 days after infection (n=6 per group).

[0408] FIG. 5F shows the survival of WT and CEACAM1/ mice after intravenous infection with 210.sup.6 PFU VSV (n=9-12 per group).

[0409] FIG. 5G shows the survival of WT and CEACAM1/ mice that were untreated or had been treated adoptively with 110.sup.7 of VSV-specific B cells (Vi10) on day 1 and had been infected on day 0 with 210.sup.6 PFU of VSV (n=4-9). * P<0.05; ** P<0.01; and *** P<0.001 (Student t-test).

[0410] The results shown graphically in FIGS. 5A to 5G show that activation of CEACAM1 is essential for an infection with VSV.

[0411] FIG. 6 shows the anti-VS V-specific IgM and IgG antibodies in wildtype (WT) and CEACAM1/ mice after intravenous infection with 210.sup.6 PFU of VSV (n=4-7 per group). * P<0.05; ** P<0.01; and *** P<0.001 (Student t-test). Data that are for two experiments (meanSEM).

[0412] The results shown graphically in FIG. 6 show that CEACAM1 is essential for anti-VSV-specific Ig production.

[0413] FIG. 7A shows the lymphoytic choriomeningitis virus (LCMV) glycoprotein-specific IgG antibody in the serum of wildtype (WT) and CEACAM1/ mice after intravenous infection with 200 PFU of LCMV-WE (n=3-6 per group).

[0414] FIG. 7B shows the liver virus titer of WT and CEACAM1/ mice 10 days after intravenous infection with 210.sup.6 PFU of LCMV-WE (n=3 per group). *** P<0.001 (Student t-test).

[0415] The results shown graphically in FIGS. 7A and 7B show that activation of CEACAM1 increases the LCMV-dependent B cell activation.

[0416] FIG. 8A shows the spleen VSV titer of WT or CEACAM1/ mice 7 h after intravenous infection with 210.sup.6 PFU of VSV (n=6 per genotype). ** P<0.01 (Student t-test).

[0417] FIG. 8B shows the interferon-alpha levels in the serum of WT or CEACAM1/ mice 2 and 4 hours after intravenous infection with 210.sup.8 PFU of VSV.

[0418] The results shown graphically in FIGS. 8A and 8B show deficit edge zones, replication and interferon induction in CEACAM1/ mice.

[0419] FIG. 9 shows the number of auto-antibody-binding cells on liver tissue slices that have been treated with serum of WT and CEACAM1/ mice 100 days after intraperitoneal injection with 500 L of pristane, and fluorescent anti-mouse IgG (n=3-5).

[0420] FIG. 10 shows the amount of virus in different organs of wildtype (WT) or CEACAM1/ mice after infection with 200 PFU of the chronic lymphocytary choriomeningitis virus strain (LCMV docile), measured 10 days after infection (n=3).

[0421] FIG. 11A shows the amount of virus in blood of wildtype (WT) or CEACAM1/ mice which had been treated with control antibodies or anti-CEACAM1 antibodies (200 g day 1) and had additionally been infected on day 0 with 210.sup.4 PFU of the chronic lymphocytary choriomeningitis virus strain (LCMV docile) (n=6).

[0422] FIG. 11B shows the alanine-aminotransferase (biomarker for liver damage) in the serum of wildtype (WT) or CEACAM1/ mice which had been treated with control antibodies or anti-CEACAM1 antibodies (200 g day 1) and had additionally been infected on day 0 with 210.sup.4 PFU of the chronic lymphocytary choriomeningitis virus strain (LCMV docile) (n=6).

[0423] FIG. 12 shows the amount of virus in different organs of wildtype (WT) mice (measured day 60) that had been infected on day 0 with 210.sup.6 PFU of the chronic lymphocytary choriomeningitis virus strain (LCMV docile) and additionally on day 16 were left untreated or treated with anti-CEACAM1 antibodies (200 g) (n=3-4).

1.1.2 Methods and Materials

1.2.1 Mice

[0424] Ceacam1.sup./ mice were reared on the generic background of C57BL/6 (back-crossed at least 8 times and up to 16 times) and were raised homozygotically. Vi10/CD45.1 mice that express a VSV-specific B cell receptor as transgene were used for cell transfer studies, and mice that express the CD45.1 transgene were used for reconstitution of bone marrow. In all studies, 6- to 8-week-old mice of the same sex were used. All animals were held in ventilated individual cages. In the survival experiments, the health state of the mice was checked twice per day. The animal experiments were carried out with approval by the state agency for nature, environment and consumer protection of Nordrhein Westfalen (Recklinghausen, Germany) and in accordance with the German animal protection law or in accordance with the institute guidelines of the Ontario Cancer Institute of the University Health Network and of McGill University, USA. Animals that displayed serious symptoms of illness or paralysis or suffered considerable weight loss during a VSV infection were taken out of the experiment and counted as deaths for the statistical analysis.

1.2.2 Virus Assays and Plaque Assays

[0425] Vesicular stomatitis virus (VSV), strain Indiana (VSV-IND, Mudd-Summers isolate) was originally obtained by Prof. D. Kolakofsky (University of Geneva, Switzerland). The virus was multiplied on BHK-21 cells having a multiplicity of infection (MOI) of 0.01. The VSV concentration was determined as described and was then plated out in the plaque technique onto Vero cells (Fink, K. et al. Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. European Journal of Immunology (2006), 36, 2094-2105.). Mice were infected intravenously with VSV in the doses stated. Virus titers were measured using a plaque assay. For this assay, organs were comminuted in Dulbecco's Modified Eagle Medium (DMEM), that contains 2% of fetal calf serum (FCS), made 1:3 over 12 stages and plated out on Vero cells. After 2-hours incubation at 37 C., a coating medium (overlay) was added and the virus preparation was again incubated at 37 C. The plaques were counted 24 h later by means of staining using crystal violet.

[0426] The strain of the lymphocytary choriomeningitis virus LCMV-WE was originally obtained by F. Lehmann-Grube (Heinrich Pette Institute, Hamburg, Germany) and multiplied in L929 cells, MC57 cells or both. Mice were infected intravenously in the dose stated. LCMV virus titer was ascertained by a plaque assay on MC57 fibroblasts as described previously (Battegay, M. et al. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J Virol Methods (1991), 33, 191-198.). In brief, comminuted organs were plated out with MC57 cells as described above and incubated at 37 C.

[0427] The strain of the lymphocytary choriomeningitis virus LCMV docile was originally obtained by F. Lehmann-Grube (Heinrich Pette Institute, Hamburg, Germany) and multiplied in L929 cells, MC57 cells, or both.

[0428] The influenza A virus was obtained by the Westendorf Working Group, University of Duisburg-Essen.

[0429] After incubation for 3 hours at 37 C., a coating medium was added and the virus preparation was again incubated at 37 C. The plaques were enumerated 72 h later by means of staining using LCMV-NP (nucleoprotein of LCMV). The cells were fixed (using 4% formaldehyde solution), permeabilized (using 1% Triton-X solution), blocked (using 10% FCS in phosphate-buffered saline PBS) and stained using anti-LCMV-NP antibodies (produced inhouse). As a secondary antibody, a conjugated anti-rabbit-IgG antibody with enhanced chemoluminescence (ECL) was used. Plaques were detected by a staining reaction (0.2 M Na.sub.2HPO.sub.4+0.1 M citric acid+30% H.sub.2O.sub.2+o-phenylenediamine dihydrochloride), wherein all chemicals were obtained from Sigma-Aldrich.

1.2.3 Test for Neutralizing Antibodies

[0430] Serum was prediluted (1:40). The complement system was inactivated at 56 C. for 30 min. In order to record IgG kinetics, diluted samples were treated with 2-mercaptoethanol (0.1 M) in order to remove IgM. Serum was adjusted 1:2 over 12 stages and was incubated with 110.sup.3 plaque-forming units (PFU) of the VSV. After 90 minutes of incubation at 37 C., the virus-serum mixture was plated out on Vero cells. After one hour, a coating medium was added and the mixture was again incubated for 24 h at 37 C. The plaques were enumerated by staining with crystal violet. Antibody titers are shown as 2- or 3-fold dilution stages (log.sub.2 and log.sub.3)-fold predilution (i.e. 40).

1.2.4 Culture of B Cells

[0431] Spleen preparations of mice of the wildtype (WT) and Ceacam1.sup./ mice were homogenized in MACS buffer (1% FCS and 0.8% 0.5 M EDTA) for magnet-activated cell sorting. B220.sup.+ B cells were isolated by positive selection with CD45R-conjugated magnetic particles (MACS Miltenyi Biotech). By means of continuous-flow cytometry, it was verified that the purity of the B220.sup.+ cells was greater than 95%. For proliferation studies, the cells were labeled with 5 M carboxyfluorescein succinimidyl ester (CFSE) and 210.sup.5 cells per well were cultured in 96-well plates in cell culture medium RMPI 1640 with addition of 10% LPS-free FCS (without lipopolysaccharide), 1% antibiotics and 0.1% 50 mM 2-mercaptoethanol. Thereafter, they were treated with anti-CEACAM1 antibody (20 g/ml, clone CC1; donated by Dr. Kathryn V. Holmes, University of Colorado, Denver, USA) or recombinant mouse-CD40 ligands (1 g/ml) in combination with mice-IL4 (10 ng/ml; R&D Systems) or LPS (10 ng/ml; Sigma Aldrich) for 48 h. Likewise, B cells (as described above) purified for inhibition experiments were cultured in the above-described medium with recombinant mouse-CD40 ligands (1 g/ml) in combination with mouse-IL4 (10 ng/ml; R&D Systems) and treated with 10 M Ibrutinib (Selleck). As a control, the same amounts of DMSO (dimethyl sulfoxide) that is used for dissolving Ibrutinib were added to wells. The cell death was measured by staining with 4,6-diamidine-2-phenylindole (DAPI; Life Technologies). For survival experiments, B cells were cultured as stated hereinbefore and the cells with Annexin-V (BD Biosciences) were thereafter stained using DAPI. At the stated time points, the proliferation and survival were determined by fluorescence-activated cell sorting (FACS). For cell signal experiments, splenocytes were dissociated in very low endotoxic-DMEM (VLE-DMEM) with addition of 10% LPS-free FCS and 1% antibiotic and treated with anti-CEACAM1 antibody (clone CC1, 20 g/ml; K. Holmes) and anti-IgM antibody (10 g/ml) (Jackson ImmunoResearch Laboratories, Inc.) for differing times at 37 C.

1.2.5 Continuous-Flow Cytometry

[0432] Peripheral blood cells were stained with antibodies anti-Ly6G (RB6-8C5), anti-CD115 (AFS98), anti-CD45R (B220; RA3-6B2), anti-CD90.2 (30-H12), anti-CEACAM1 (CC1; with corresponding isotype control anti-IgG1 [M1-14D12]), anti-IgD (11-26c), anti-CD93 (AA4.1), anti-CD19 (1D3) (all from eBioscience) and anti-IgM (II/41; BD Biosciences). Isolated bone marrow cells were suspended in FACS buffer (0.5 M EDTA, 0.1% sodium azide, 1% FCS in PBS) and incubated with antibodies anti-CD45R (B220; RA3-6B2), anti-IgD (11-26c), anti-IgM (II-41), anti-CEACAM1 (CC1), anti-CD24 (M1/69) (all from eBioscience), anti-CD43 (1B-11) and anti-BP1 (6C3) (from BioLegend). Inguinal lymph nodes were disaggregated in FACS buffer and the cells were stained for antibodies anti-CD45R (B220; RA3-6B2), anti-CD19 (1D3), anti-IgD (11-26c) (all from eBioscience) and anti-IgM (II/41) (BD Biosciences). Spleens were dissociated in FACS buffer and splenocytes were incubated with antibodies anti-CD45R (B220; RA3-6B2), anti-CD19 (1D3), anti-CD93 (AA4.1), anti-CD21/35 (8D9), anti-CD23 (B3B4), anti-IgD (11-26c), anti-CEACAM1 (CC1), anti-CD45.1 (A20), anti-CD45.2 (104) (all from eBioscience) and anti-IgM (II/41) (BD). Human peripheral blood samples were stained with antibodies anti-IgD (IA6-2) and anti-CD27 (M-T271) (both from BD Biosciences) and antibody anti-CEACAM1 (mAB, B3-17) (from Dr. Singer, Essen). Peritoneal B cells were stained for antibodies anti-CD19 (1D3), anti-CD45R (B220; RA3-6B2), anti-IgM (II/41) (all from eBioscience) and anti-CD5 (53-7.3) (BD Biosciences) and anti-CD43 (1B-11) (from BioLegend). Dead cells were discriminated by staining with propidium iodide (PI, eBioscience) and/or DAPI and were excluded from all analyses apart from blood analyses. For cell signal experiments, cells were fixed and permeabilized (BD Phosflow, BD Biosciences) as per the manufacturer's instructions. The cells were stained with antibody anti-Btk (pY223)/Itk (pY180) (BD Phosflow). All antibodies were diluted 1:100 to their starting concentration in FACS buffer. For quantitative determination of the total cell counts, FACS particles were used (BD Biosciences). All stained cells were analyzed in a continuous-flow cytometer of the LSRII type or FACSFortessa (BD Biosciences) type, and the data were analyzed using Flowjo software.

1.2.6 Gating Strategy for Identifying Subgroups of B Cells

[0433]

TABLE-US-00004 TABLE 1 Gating Strategy for Identifying Subgroups of B Cells Origin B cell subgroup Marker Bone marrow immature, newly formed B220.sup.+ CD43.sup. IgD.sup./low IgM.sup.+ mature recirculating, B220.sup.+ CD43.sup. IgD.sup.high IgM.sup. follicular (FO) Blood immature, newly formed B220.sup.+ IgD.sup./low IgM.sup.+ mature recirculating, B220.sup.+ IgD.sup.high IgM.sup. follicular (FO) native-like B220.sup.+ CD93.sup.high IgD.sup. IgM.sup. Lymph nodes immature, newly formed B220.sup.+ CD19.sup.+ IgD.sup./low IgM.sup.+ mature recirculating, B220.sup.+ CD19.sup.+ IgD.sup.high IgM.sup. follicular (FO) Spleen Marginal zone (MZ) B220.sup.+ CD19.sup.+ CD93.sup./low CD21/35.sup.high CD23.sup. follicular (FO) B220.sup.+ CD19.sup.+ CD93.sup./low CD21/35.sup.int CD23.sup.+ transitional T1 B220.sup. CD19.sup. CD93.sup.+ CD23.sup. IgM.sup.high transitional T2 B220.sup. CD19.sup. CD93.sup.+ CD23.sup.+ IgM.sup.high transitional T3 B220.sup. CD19.sup. CD93.sup.+ CD23.sup.+ IgM.sup.low

1.2.7 LCMV Glycoprotein GP1-Specific IgG Measurements

[0434] The detection of LCMV glycoprotein GP1-specific IgG by ELISA (Enzyme Linked Immunosorbent Assay) has already been described (Recher, M. et al. Deliberate removal of T cell help improves virus-neutralizing antibody production. Nature immunology (2004), 5, 934-942.). In brief, flat-bottomed 96-well plates Nunc Immuno Plates (Thermo Scientific) were coated with anti-human IgG (Jackson ImmunoResearch Laboratories, Inc) ENREF 60 in coating buffer (0.1 M Na.sub.2CO.sub.3+0.1 M NaHCO.sub.3; pH 9.6) overnight at 4 C. On the next day, the plates were washed with a wash buffer (PBS with 0.05% Tween20) and a blocking of unspecific binding was performed for 2 hours with 2% FCS in PBS. The plates were incubated for 3 hours at room temperature with LCMV Gp-Fc supernatant (produced inhouse). The plates were washed and established with prediluted (1:20) serum over 12 recesses with dilutions of 1:3 in sequential recesses. After an incubation of 90 minutes, the plates were incubated with horseradish peroxidase (HRP)-conjugated anti-mouse-IgG antibodies (Sigma). After one hour of incubation, the plates were developed as described hereinafter.

1.2.8 ELISA Measurements

[0435] For detection of VSV-specific anti-IgG- and anti-IgM antibodies, flat-bottomed 96-well plates Nunc Immuno Plates (Thermo Scientific) were coated with baculovirus VSV-GP (Lang, K. S. et al. MyD88 protects from lethal encephalitis during infection with vesicular stomatitis virus. European journal of immunology (2007), 37, 2434-2440) in coating buffer 0.1 M NaCO.sub.3 (0.1 M Na.sub.2CO.sub.3+0.1 M NaHCO.sub.3; pH 9.6) overnight at 4 C. On the next day, the plates were washed with a wash buffer (PBS with 0.05% Tween20) and a blocking of unspecific binding with 2% FCS in PBS was performed for 1 to 2 hours. The plates were washed once and established with prediluted (1:15) serum over 12 recesses with dilutions of 1:3 in sequential recesses. The plates were incubated at room temperature for 2 h. The plates were washed with wash buffer and incubated with HRP-conjugated anti-mouse-IgG-antibody (Sigma) or anti-mouse-IgM-antibody (Sigma) for 30 to 60 min. The plates were washed and incubated in the dark with 1TMB substrate solution (eBioscience), after which 10% H.sub.2SO.sub.4 solution was added in order to interrupt the staining reaction. The optical density was measured at 450 nm (FLUOstar Omega, BMG LABTECH). Various immunoglobulin isotypes and subtypes were measured in nave serum of WT mice and Ceacam1.sup./ mice, as has been described (Recher, M. et al. B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B cell compartment in mice. Blood (2012), 119, 2819-2828.).

1.2.9 Formation of Mouse-Anti-Human-CEACAM1-Antibody

[0436] Female mice from 8 to 10 weeks in age were immunized in three stages with human CEACAM1-Fc (50 g/90 l in PBS) mixed with Gerbu adjuvants MM (60 l) (ideally on day 0, day 14 and day 21; intraperitoneally (i.p.) the first immunization, subcutaneously (s.c.) the second and third immunization). The amount of the first immunization was twice the amount of all subsequent immunizations. One week after the third immunization, blood was withdrawn from the mice for obtaining serum. In order to test whether the titer was sufficient, an ELISA or a continuous-flow cytometric analysis was carried out. The titer of day 0 to day 21 had generally increased 100 to 1000 fold. Mice having a sufficient titer were boosted with 25 g of human CEACAM1-Fc dissolved in sterile PBS without adjuvant i.v. and i.p., four days before the mice were killed and the splenocytes (spleen cells) were obtained.

[0437] The mice were killed by cervical fracture and the spleen was removed under aseptic conditions. The spleen was squashed through a 70 m nylon cell sieve. Splenocytes were transferred into a 50 ml Falcon tube and washed three times with DMEM medium that did not contain any additives (e.g. FCS). In parallel, the fusion partner cell line (the mice myeloma cell line NS1/0) was likewise washed in DMEM. Thereafter, the splenocytes and myeloma cells were mixed in a ratio of 5:1 and centrifuged for 5 min at 2000 rpm. Then, the supernatant was removed and the cell pellet was used for the fusion. For this purpose, 1 ml of PEG was slowly added to the cell pellet and mixed carefully within 1 min. Thereafter, PEG was diluted very slowly with warm DMEM according to the following protocol: 1 min=1 ml, 1 min=1 ml, 1 min=1 ml, 1 min=1.5 ml, 1 min=1.5 ml, 1 min=2.5 ml, 1 min=2.5 ml, 1 min=5 ml, 1 min=5 ml, 1 min=5 ml, 1 min=5 ml, 1 min=5 ml, 1 min=5 ml.

[0438] Then, the fused cells were centrifuged (10 min at 800 rpm) and the supernatant was carefully removed. Then, the cell pellet was resuspended (8 ml of HAT medium per 10.sup.7 NS/1/0 cells) and the cells were plated out in flat-bottomed 96-hole cell culture plates for HAT selection. The medium was removed every third day. After 10 to 14 days, when cell clones were visible, and the medium became yellow due to the pH shift, supernatants were tested for secreted anti-human-CEACAM1 antibody by means of continuous-flow cytometry and ELISA. Positive cell clones were subcloned (=monoclonal), further tested and used for a mAb production.

[0439] Subsequently, mAbs were freed from the cell culture supernatant (for example 500 ml) via protein G-sepharose columns (column chromatography), eluted by pH shift with the use of 0.1 M glycine buffer (pH 2.5) and dialyzed against sterile PBS. Sterile-filtered mAb solution was used in order to determine the Ig concentration by measuring the OD.sub.280 nm and the concentration was calculated using the formula OD.sub.280 nm/1.36=x mg/ml.

1.2.10 Statistical Analysis

[0440] Data were expressed in figures as meansS.E.M. (statistical standard error of mean) and in tables as meansS.D. (standard deviation). The Student t-test (paired or unpaired, one-sided or two-sided) was used in order to determine statistically significant differences between groups. Significant differences between different groups were determined by one-way analysis of variance (ANOVA), with post-hoc tests as per Bonferroni or Dunnett. Survival was compared with log-rank tests (Mantel-Cox tests). The statistical level of significance was established as P<0.05.

1.2.11 Characterization of Antibody Binding

[0441] Cells:

[0442] CHO cells were transfected with entire CEACAM1 or with CEACAM1 without N domain (Muturi HAT et al. PLoS One. 2013 Sep. 11; 8(9):e74654.).

[0443] ELISA:

[0444] Sandwich ELISA was coated with 0.25 g/100 microL/well of anti-CEA (Dako). ELISA was washed and remaining binding sites blocked. Subsequently, CEACAM1 or CEACAM1deltaN (therefore CEACAM1 without N-domain, CEACAM1dN) was added thereto. CEACAM1 and CEACAM1deltaN were obtained from CHO transfectants. The ELISA was then incubated with differing antibodies. After 4 hours of incubation, the ELISA was washed and incubated with anti-mouse Ig-HRP. After 1 hour, the substrate TMB was added and the absorption measured at 450 nm.

[0445] FACS:

[0446] For analysis of antibody binding to human immune cells, PBMCs (=peripheral blood mononuclear cells) were incubated for at least 20 minutes at 4 C. with anti-CEACAM1 antibodies. Thereafter, the cells were washed and anti-mice IgG-APC (eBioscience) together with anti-CD8 antibodies (eBioscience) were added thereto. After 30 minutes, the cells were washed and the fluorescence measured in FACS.

1.2.12 Activation of T Cells

[0447] In vitro Activation of CD8.sup.+ T cells: In order to analyze the effect of anti-CEACAM1 antibody on the proliferation of CD8+ T cells, PBMCs of HLA-A2+CMV+ healthy donors were incubated together with CMV peptide PP65-73 or influenza matrix peptide 57-68 together with IL2 in RPMI 10% human serum for 10 to 13 days. Thereafter, the cells were restimulated with antigen and intracellular IFN-gamma was measured.

[0448] Intracellular cytokine staining: 100 000 cells were transferred to 96-well plate (U-shaped bottom). Cells were treated with peptide 1 (1 g/ml) or left untreated. After 2 hours, Brefeldin A was added (Sigma). After a further 6 to 8 hours, cells were incubated with anti-CD8 antibody (eBiosciences). Cells were then fixed for 10 minutes with formalin (2% in PBS) and washed 2 with saponin in FACS buffer. Subsequently, cells were incubated with anti-IFN-gamma antibody (eBiosciences) and the fluorescence was measured in the FACS.

[0449] Results: The experimental results are shown in the tables hereinafter:

[0450] Table 2, B3-17, but not 18-20 and 6G5J can bind in the absence of N domains: the table shows the binding of the antibodies B3-17, 18-20 and 6G5J to CEACAM1 and CEACAM1 without N-domain (=CEACAM1dN) measured in the ELISA. The table shows meansSD (standard deviation) of the absorption at 450 nm. The binding of antibody 18-20 to CEACAM1 was significantly higher than to CEACAM1 dN (18-20 CEACAM1 versus 18-20 CEACAM1 dN, p<0.05, t-test). The binding of 6G5J to CEACAM1 was significantly higher than to CEACAM1 dN (6G5J CEACAM1 versus 6G5J CEACAM1 dN p<0.05, t-test). The binding of B3-17 to CEACAM1 was not higher than to CEACAM1 dN (B3-17 CEACAM1 versus B3-17 CEACAM1 dN).

TABLE-US-00005 TABLE 2 WT CEACAM1 CEACAM1 dN (Mean SD, n) (Mean SD, n) (Mean SD, n) B3-17 0.05 0.003, 3 0.62 0.048, 3 0.910 0.056, 3 18-20 0.06 0.004, 3 1.30 0.093, 3 0.053 0.0057, 3 6G5J 0.054 0.004, 3 1.09 0.088, 3 0.066 0.0053, 3

[0451] The experimental results given in table 2 show that the antibodies that have an antibody binding site CDR2.sup.H of the sequence SEQ ID No. 21 (i.e. antibodies 18-20 and 6G5J), in contrast to the antibody B3-17 that does not have such an antibody binding site CDR2.sup.H, bind effectively to the N-domain of CEACAM1.

[0452] Table 3: B3-17 and 18-20 bind human CD8.sup.+ T cells: the table shows the binding of isotype control and the antibodies B3-17 and 18-20 to CD8.sup.+ T cells from the blood of healthy donors. The table shows meansSD of the mean fluorescence intensity. The binding of antibody B3-17 to CD8.sup.+ T cells is significantly higher than the binding of isotype p<0.05 (paired t-test). The binding of 18-20 to CD8.sup.+ T cells is significantly higher than the binding of isotype p<0.05 (paired t-test).

TABLE-US-00006 TABLE 3 Isotype B3-17 18-20 (Mean SD, n) (Mean SD, n) (Mean SD, n) Mean SD 436 57.38, 10 913 298.80, 10 632 72.72, 10

[0453] The experimental results given in table 3 show that the antibodies also bind to (human) T cells. These were then, in the case of the antibody 18-20 and 6G5J according to the present invention, surprisingly strongly activated (see below tables 4-6), whereas antibody B3-17 had a significantly lower activating effect when stimulated.

[0454] Table 4, 18-20, 6G5J, but not B3-17 activates CD8.sup.+ T cells: PBMCs of healthy donors were incubated with or without CMV peptide in the presence or absence of isotype control and the antibodies 18-20, 6G5J or B3-17. On day 10, the cells were no longer stimulated or were restimulated for 8 hours with CMV peptide. Intracellular IFN-gamma was measured in the FACS. The table shows the percentageSD of the IFN-gamma-positive CD8.sup.+ T cells. Presence of antibody 18-20 led to the significant increase of the IFN-gamma positive T cells (CMV stimulated versus CMV, 18-20 stimulated, p<0.05, t-test). Presence of B3-17 led to no significant increase in IFN-gamma positive T cells (CMV stimulated versus CMV, B3-17 stimulated, p=0.344, t-test). 18-20 stimulates significantly better than B3-17 (CMV, 18-20 stimulated versus CMV, B3-17 stimulated, p<0.05, t-test).

TABLE-US-00007 TABLE 4 Not stimulated Stimulated (Mean SD, n) (Mean SD, n) None 0.111 0.104, 3 0.367 0.048, 3 CMV 0.177 0.131, 3 0.540 0.287, 3 CMV + Isotype 0.221, 2 0.372, 2 CMV + 18-20 0.296 0.165, 3 3.876 2.598, 3 CMV + 6G5J 0.112 0.067, 3 2.951 2.200, 3 CMV + B3-17 0.219 0.148, 3 0.465 0.095, 3

[0455] Table 5, 18-20 activates influenza-specific CD8.sup.+ T cells: PBMCs of healthy donors were incubated with influenza-peptide together with anti-CD28 in the presence or absence of 18-20 antibody. After 13 days, the cells were restimulated with influenza peptide and after 6 hours intracellular IFN-gamma was measured. The table shows the percentageSD of the IFN-gamma positive CD8.sup.+ T cells. The presence of antibody 18-20 led to significantly more IFN-gamma-producing T cells (CD28 stimulated versus CD28+18-20 stimulated, p<0.05 t-test).

TABLE-US-00008 TABLE 5 Not stimulated Stimulated (Mean SD, n) (Mean SD, n) CD28 1.12 1.99, 5 4.08 4.33, 8 CD28 + 18-20 0.217 0.150, 3 11.74 9.914, 10

[0456] Table 6, humanized 18-20 activates human CD8.sup.+ T cells: PBMCs of healthy donors were incubated with or without CMV peptide in the presence or absence of humanized 18-20 antibody. On day 10, the cells were restimulated with CMV peptide and after 8 hours, intracellular IFN-gamma in the FACS was measured. Table shows percentageSD of the IFN-gamma positive CD8.sup.+ T cells. The presence of humanized antibody 18-20 led to a significant increase in the IFN-gamma-positive T cells (CMV stimulated versus CMV+hu18-20 stimulated, p<0.05, t-test).

TABLE-US-00009 TABLE 6 Not stimulated Stimulated (Mean SD, n) (Mean SD, n) None 0.106 0.109, 3 0.211 0.017, 3 CMV 0.186 0.180, 3 2.64 3.049, 3 CM + hu18-20 0.456 0.250, 3 7.44 5.57, 3

[0457] The following binding values were determined for binding of the antibody to CEACAM1:

[0458] Antibody 18-20: K.sub.d 26 nM; K.sub.on: 1.210.sup.4; K.sub.off: 3.510.sup.4

[0459] Antibody 6G5J: K.sub.d 23 nM; K.sub.on: 1.010.sup.4; K.sub.off: 3.110.sup.4

[0460] Antibody B3-17: K.sub.d 10 nM; K.sub.on: 3.410.sup.4; K.sub.off: 3.410.sup.4

[0461] All three antibodies are accordingly binding in the lower double figure nanomolar range. The differences in the activation of the T cells therefore do not arise via different total binding strengths, but via the targeted binding to the N-domain of the CEACAM1 by the antibodies 18-20 and 6G5J according to the present invention.

FURTHER PREFERRED EMBODIMENTS

[0462] The present invention also relates to a substance for application in the therapy of viral infections and/or viral infectious diseases, wherein the substance activates the expression and/or function of CEACAM1.

[0463] In addition, the present invention relates to a substance for application in the therapy of B-cell-dependent diseases, wherein the substance inhibits the expression and/or function of CEACAM1.

[0464] In addition, the present invention relates to a substance for application in the diagnosis of viral infections, viral infectious diseases and/or B-cell-dependent diseases, wherein the substance is used for detection of the expression and/or function of CEACAM1.

[0465] The present invention further relates to an antibody, a therapeutic antibody, a variable antibody heavy chain (V.sub.H) domain, a variable antibody light chain (V.sub.L) domain, an isolated nucleic acid encoding a variable antibody heavy chain (V.sub.H) domain, an isolated nucleic acid encoding a variable antibody light chain (V.sub.L) domain, a hybridoma cell and also a method for producing an antibody.

[0466] Further preferred embodiments are: [0467] 1. Substance for application in the therapy of viral infections and/or viral infectious diseases, characterized in that the substance activates the expression and/or function of CEACAM1. [0468] 2. Substance according to embodiment 1, characterized in that CEACAM1 is CEACAM1 as per SEQ ID No. 1. [0469] 3. Substance according to embodiment 1 or 2, characterized in that the substance is a substance directed against CEACAM1. [0470] 4. Substance according to any one of the preceding embodiments, characterized in that the substance is an antibody directed against CEACAM1 (anti-CEACAM1 antibody). [0471] 5. Substance according to embodiment 4, characterized in that the antibody comprises a variable antibody heavy chain (V.sub.H) domain selected from the group consisting of variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 3, variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 7 and variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 11, and/or a variable antibody light chain (V.sub.L) domain selected from the group consisting of variable antibody light chain (V.sub.L) domain as per SEQ ID No. 5, variable antibody light chain (V.sub.L) domain as per SEQ ID No. 9 and variable antibody light chain (V.sub.L) domain as per SEQ ID No. 13. [0472] 6. Substance according to one of embodiments 1 to 3, characterized in that the substance is the soluble protein UspAl of Moraxella catarrhalis as per SEQ ID No. 15. [0473] 7. Substance according to one of embodiments 1 to 3, characterized in that the substance is the soluble protein Opa of Neisseria gonorrhoeae as per SEQ ID No. 17. [0474] 8. Substance according to one of embodiments 1 to 3, characterized in that the substance is the soluble variable protein P5 of Haemophilus influenza as per SEQ ID No. 18. [0475] 9. Substance according to one of embodiments 1 to 3, characterized in that the substance is the soluble human recombinant CEACAM1 fusion protein as per SEQ ID No. 19. [0476] 10. Substance according to one of the preceding embodiments, characterized in that the viral infections and/or infectious diseases are selected from the group consisting of viral hepatitis, hepatitis B, hepatitis C, HIV infection, Aids, influenza, poliomyelitis, virus-induced myocarditis, glandular fever, herpes simplex, cytomegalie, rabies and Ebola. [0477] 11. Drug for application in the therapy of viral infections and/or viral infectious diseases containing at least one substance according to one of the preceding embodiments. [0478] 12. Antibody comprising a variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 3 and/or a variable antibody light chain (V.sub.L) domain as per SEQ ID No. 5. [0479] 13. Therapeutic antibody comprising a variable antibody heavy chain (V.sub.H) domain that is selected from the group consisting of variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 3, variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 7 and antibody heavy chain (V.sub.H) domain as per SEQ ID No. 11, and/or a variable antibody light chain (V.sub.L) domain which is selected from the group consisting of variable antibody light chain (V.sub.L) domain as per SEQ ID No. 5, variable antibody light chain (V.sub.L) domain as per SEQ ID No. 9 and antibody light chain (V.sub.L) domain as per SEQ ID No. 13. [0480] 14. Variable antibody heavy chain (V.sub.H) domain as per SEQ ID No. 3 or SEQ ID No. 7. [0481] 15. Variable antibody light chain (V.sub.L) domain as per SEQ ID No. 5 or SEQ ID No. 9. [0482] 16. Isolated nucleic acid encoding a variable antibody heavy chain (V.sub.H) domain, wherein the nucleic acid comprises a nucleotide sequence or consists of a nucleotide sequence that is selected from the group consisting of SEQ ID No. 4 and SEQ ID No. 8. [0483] 17. Isolated nucleic acid encoding a variable antibody light chain (V.sub.L) domain, wherein the nucleic acid comprises a nucleotide sequence or consists of a nucleotide sequence that is selected from the group consisting of SEQ ID No. 6 and SEQ ID No. 10. [0484] 18. Hybridoma cell that produces an antibody according to embodiment 12 or 13. [0485] 19. Method for producing an antibody, in particular an antibody according to embodiment 12 or 13, comprising the following steps: [0486] a) fusing B cells, which originate from an experimental animal immunized against an antigen, and myeloma cells, forming hybridoma cells, [0487] b) selecting the hybridoma cells, [0488] c) isolating hybridoma cells that produce antibodies directed against the antigen, [0489] characterized in that the antigen is CEACAM1 as per SEQ ID No. 1 or a fragment, in particular epitope, thereof.

[0490] The present invention is not limited to embodiments described herein; reference should be had to the appended claims.